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GENERAL INTRODUCTION
Cocaine Dependence
Psycho-stimulant abuse and addiction is a serious medical, economic and health
problem for which there are no effective pharmacotherapies. Cocaine is one of the most
commonly abused psychostimulants. The acute rewarding effects produced upon
administration of cocaine, followed by cravings and relapse after a period of abstinence, are
the hallmark features of addiction to cocaine. Despite the worldwide abuse and almost a
decade worth of research into potential treatments, an effective treatment medication remains
elusive (Gorelick, Gardner, & Xi, 2004)
Cocaine is a crystalline tropane alkaloid obtained from the leaves of the Erythroxylon
coca plant. Pharmacologically, cocaine has many prominent actions. It is a local anesthetic, it
increases alertness and reduces fatigue, increases motor activity and, importantly, it is a
powerful positive reinforcer. Cocaine has been used for years as a recreational stimulant and
for its local anesthetic properties. Today, cocaine is considered to be one of the most
addictive substances known and epidemiological studies show that cocaine addiction is a
markedly persistent problem in the US. Nearly six million Americans (age 12 or older) used
cocaine in 2001 (SAMHSA 2003) and the Office of National Drug Control Policy estimates
that approximately three million individuals chronically use cocaine. Cocaine dependence is
known to develop over a period of time, and becomes a chronic, relapsing disorder
characterized by compulsive drug-seeking and drug use despite the negative consequences
associated with it (Dackis & O'Brien, 2001). Cocaine is known to elevate mood, induce
euphoria, reduce fatigue and increase task performance. It is these positive reinforcing
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effects, coupled with the severity of the psychological withdrawal side effects that is
responsible for the high rate of relapse seen in addicts attempting to break the addiction.

Mesolimbic DA hypothesis of psycho-stimulant reward

It is thought that cocaine produces its strong reinforcing effects by binding to and
blocking the dopamine (DA) uptake transporter (DAT) particularly in the mesolimbic DA
reward pathway (Ritz, Lamb, Goldberg, & Kuhar, 1987). Blockade of the transporter inhibits
the reuptake of DA into the presynaptic nerve terminals and, therefore, increases its
concentration in the synapse, leading to the positive reinforcing effects associated with
cocaine (Koe, 1976).
The mesolimbic DA system is critical in mediating the rewarding properties of
cocaine (Koob & Swerdlow, 1988; Self & Nestler, 1995; Wise, 2005) and, hence, plays a
large role in cocaine addiction. The pathway originates in the ventral tegmental area (VTA)
in the midbrain and projects to the nucleus accumbens (NAc), prefrontal cortex (PFc) and
amygdala in the forebrain. Increased DA neurotransmission, particularly in the mesolimbic
DA reward pathway (Di Chiara, 1995), and indirect activation of DA receptors (Spealman,
Bergman, Madras, Kamien, & Melia, 1992), has been shown to play an important role in the
positive reinforcing effects of cocaine that are entwined with the euphoria associated with
cocaine’s abuse (Koob & Swerdlow, 1988; Wise, 2005).
There is an abundance of evidence supporting the role of this DA system in the
rewarding properties of many drugs of abuse, starting with the fact that cocaine and other
abused drugs have been shown to increase extracellular DA in the NAc (Self DW 1995, Wise
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RA2005). It is also widely known that cocaine is readily self-administered by rodents and
non-human primates and that this effect can be attenuated through the use of high dose DA
receptor antagonists (Gardner, 2000).

Pharmacological treatments for cocaine abuse
Since it is thought that cocaine produces its strong reinforcing effects through action
within the DA reward pathway, it seems reasonable that one cocaine treatment strategy would
involve manipulating this DA reward pathway. There are two prominent pharmacological
approaches to manipulate this pathway; either by using agents that antagonize the brain DA
receptors or by agents that promote their activation, directly or indirectly. However, despite
several decades of research into cocaine dependence, an effective treatment strategy remains
elusive. A number of approaches have been explored, including DA receptor antagonism (de
Lima, de Oliveira Soares, Reisser, & Farrell, 2002), anti-depressants and anti-convulsants
(Gorelick, et al., 2004), and more recently a cocaine vaccination to prevent entry of cocaine
into the brain (Martell, Mitchell, Poling, Gonsai, & Kosten, 2005). However, of all the
potential treatment strategies investigated, DAT agonist substitution appears to have
generated the greatest interest to date.

DAT Agonist Substitution as a Potential Treatment Strategy
Given the success of methadone replacement treatment for heroin addiction and the
nicotine patch for the cessation of smoking, it seems plausible that a similar strategy may
work for cocaine addiction. Cocaine produces its reinforcing effects by binding to and
blocking the DAT (Ritz, et al., 1987). This is understood to cause an increase in the extra
cellular DA levels, leading to an increased DA receptor activation (Fig 1). It is also thought
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that the faster an abused drug enters the brain, the faster extracellular DA is increased and the
higher the abuse potential of the drug (Kimmel, O'Connor, Carroll, & Howell, 2007).
Therefore, an effective replacement therapy could potentially be a DAT inhibitor, to produce
some cocaine-like effects, but with a slower onset of action to convey a lower abuse potential
than cocaine itself. Producing such a compound is proving to be difficult, as achieving a
balance between possessing some cocaine-like effects but with lower reinforcing efficacy and
with adequate safety has yet to be achieved.

Figure 1: Diagrammatic representation of DAT functioning normally (left hand panel)
and in the presence of cocaine (right hand panel) (CNSforum.com)
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DAT Inhibitors as Potential Treatments for Cocaine Dependence
A number of compounds have been investigated as potential agonist replacement
therapies. These include bupropion, benztropines, tropanes, mazindol and substituted
piperazines. Some of these compounds have demonstrated cocaine-like behavioural profiles
in animal models, and some have shown potential to act as “agonist” therapies, however none
have proven 100% effective as a replacement therapy, either due to low efficacy in clinical
studies, or because of their toxic effects, or because of a high abuse potential of their own
(Gorelick, et al., 2004).
Bupropion is an atypical anti-depressant and smoking cessation aid that is known to
inhibit dopamine and noradrenaline reuptake with relatively little inhibitory action at the
SERT (Richelson & Pfenning, 1984). Bupropion has high uptake inhibition at the DAT, and
since this activity is known to be responsible for the high abuse liability of cocaine-like
psychostimulants, it is not surprising that pre-clinical studies have shown bupropion to be
self-administered in monkeys and rats at levels similar to cocaine (Bergman, Madras,
Johnson, & Spealman, 1989; Tella, Ladenheim, & Cadet, 1997). Although bupropion has
been marketed as an anti-depressant and a smoking cessation aid for years, it has not had a
significant incidence of abuse (Nieuwstraten & Dolovich, 2001; Wilkes, 2008). The discorrelation of the animal laboratory studies and the actual abuse of bupropion suggests that
results from pre-clinical studies are not always clinically predictive. This suggests that DAT
inhibitors, whilst sometimes conveying cocaine-like effects, may not necessarily always
possess abuse liability. This could, in part, be due to the route of administration. An early
study showed that peak concentrations of bupropion in brain tissue of rats and mice after p.o
administration of 10 mg/kg were approximately 10% of concentrations measured after i.v
administration of the same dose (Butz, Welch, & Findlay, 1982). However, despite the
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cocaine-like, preclinical profile of bupropion, it did not prove to be a successful replacement
therapy for cocaine dependence it was thought it could be (Oliveto et al., 2001).
Research to find a DAT inhibitor, without abuse potential, to act as a potential therapy
for cocaine dependence has continued beyond bupropion. Benztropine possesses a tropane
ring, a predominant feature of the cocaine molecule and is a potent DAT inhibitor (Horn AS,
1971). However, in animal models of drug abuse, benztropine did not demonstrate cocainelike behaviour despite having a high affinity for the DAT (J. L. Katz, Newman, &
Izenwasser, 1997; Newman, Allen, Izenwasser, & Katz, 1994). In fact, benztropine itself is
an approved medication for the treatment of Parkinson Disease, attributable to its DAT
inhibition, but does not appear to possess the abuse liability of cocaine. Benztropine was
studied in a Phase II clinical trial to determine its efficacy in affecting stimulated craving to
cocaine cues, although there are no published results of this study (ClinicalTrials.gov
identifier NCT00000333.)

More recent studies with benztropine analogs have shown that

these newer compounds have cocaine-like behaviour but with an apparent lower abuse
liability than cocaine itself (Ferragud et al., 2009; Hiranita, Soto, Newman, & Katz, 2009). Nsubstituted benztropine analogs were studied in rats to characterize their addictive-like
properties and their effects on cocaine self-administration (Ferragud, et al., 2009). Results in
these open field tests and drug self-administration assays showed that the N-substituted
benztropine analog, AHN-1055, produced robust and sustained locomotor activity and also
enhance cocaine-induced locomotor stimulation. AHN-1055 showed weak reinforcing
efficacy in progressive ratio studies and did not promote cue- induced relapse. AHN-1055
also produced a dose dependent decrease in cocaine intake in rats with a history of cocaine
self-administration (Ferragud, et al., 2009). Another recent study investigating the reinforcing
effects of benztropine analogs and their effects on cocaine self-administration showed that
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benztropine and its newer analogs are less effective than cocaine in producing behavioural
effects that are predictive of abuse liability and therefore may be suitable candidates as
potential cocaine dependence medications (Hiranita, et al., 2009).
Tropane analogs were among the first DAT inhibitor compounds that were
investigated as cocaine replacement therapies. RTI-113 and PTT both have a high selectivity
for DAT verses SERT and NET and both were shown to decrease cocaine self-administration
in non-human primates (Negus, Mello, Kimmel, Howell, & Carroll, 2008). However, both
compounds also decreased food maintained responding at similar doses required to decrease
cocaine self administration. These non-specific, behaviourally toxic effects may hinder their
potential to be developed as replacement therapies for cocaine (Howell, Czoty, Kuhar, &
Carrol, 2000; Nader, Grant, Davies, Mach, & Childers, 1997). Further studies with
phenyltropane analogues have shown that high affinity DAT inhibitors with a slower rate of
onset and longer duration of action decreased cocaine intake and also maintained less cocaine
self administration across a range of conditions (Lile et al., 2002).
RTI-336 (3-beta-(4-chlorophenyl)-2betas-[3-(4’-methlyphenyl)isoxazol-5-yl]tropane)
is a novel DAT inhibitor that has a slower onset and longer duration of action than cocaine
(F. I. Carroll, Howard, Howell, Fox, & Kuhar, 2006; Kimmel, et al., 2007) and is more
selective for the DAT relative to the SERT and NET (Carroll FI et al., 2006). RTI-336 dose
dependently attenuated cocaine self-administration in both rats and non-human primates but
only at very high doses (Howell, Carroll, Votaw, Goodman, & Kimmel, 2007). RTI-336 was
also shown to be reliably self-administered and also generalized to cocaine’s discriminative
stimulus (Howell, et al., 2007). This study provided evidence to suggest that RTI-336 may
have its own abuse potential although it did maintain lower rates of self-administration when
compared to cocaine suggesting it may have a lower abuse potential than cocaine itself. RTI7

336 is a promising candidate and has been tested in a Phase 1 clinical trial in healthy male
subjects (www.clinicaltrials.gov/ct/show/NCT00808119) although no results have been
published.
Mazindol is an anorexic compound that has also been used to label the cocaine
binding site on the dopamine transporter (Ritz, et al., 1987). It has been shown to inhibit
reuptake of DA, 5-HT and NET but does so without showing the robust reinforcing effects
seen with cocaine (Bergman, et al., 1989; Wilson & Schuster, 1976). Mansbach et al (1993)
showed that mazindol generalized to cocaine in discrimination studies and also reduced selfadministration of cocaine, albeit at doses that also reduced food maintained behavior
(Mansbach & Balster, 1993) . A further study showed that mazindol had positive reinforcing
properties in rhesus monkeys trained to self-administer cocaine (Wilson and Schuster 1976).
Given these properties mazindol was considered to be a suitable candidate as a cocaine
replacement therapy, however, a double-blind placebo-controlled study showed that patients
treated with mazindol versus placebo showed no response differences (Stine, Krystal, Kosten,
& Charney, 1995). Further studies were suggested with higher doses of mazindol but there
were concerns about safety with using higher doses and therefore were not pursued (Preston,
Sullivan, Berger, & Bigelow, 1993).
GBR-12909 is a 1,4-dialkylpiperazine and was among the first compounds to be
characterized as a selective and high affinity DAT inhibitor (van der Zee, Koger, Gootjes, &
Hespe, 1980), being several fold less potent at 5-HT and NE transporters (Andersen, 1987;
Hirate & Kuribara, 1991; Preti, 2000) and much research has characterized its behavioural
profile (Rothman & Glowa, 1995). It was determined to have a slower onset and longer
duration of action than cocaine (Kelley & Lang, 1989; Rothman et al., 1992; Rothman et al.,
1991), in part due to its slower dissociation and higher affinity at the DAT (Reith, Sershen, &
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Lajtha, 1981). It is the most extensively studied piperazine derivative in terms of its potential
as a cocaine substitute. GBR-12909 has been shown to increase locomotor activity and
inhibit cocaine self-administration in rats and non-human primates (Schenk, 2002; Tella,
1995). GBR-12909 generalizes to cocaine in discrimination studies (Holtzman, 2001), is also
self-administered in rats and non-human primates, and shows similar break points to cocaine
in progressive ratio studies (Roberts, 1993). These latter results suggest that GBR-12909
may have its own inherent abuse potential. GBR-12909 has also been shown to attenuate the
cocaine-induced increase in extracellular dopamine in rat nucleus accumbens (Baumann et
al., 1994). GBR-12909 is one of the few DAT inhibitors that has been tested in clinical trials
as a potential agonist therapy for treating cocaine dependence. Unfortunately the trial was
halted after Phase I due to cardiac toxicity (Vocci & Elkashef, 2005) thought to be cause by
an enhanced QT interval (Herman BH et al., 2005).

Rationale for Study
Given the available research, and data that shows that cocaine’s abuse related effects
are attributable to its inhibitory actions at the DAT (Ritz et al., 1987), it has been determined
that a potential treatment for cocaine dependence could involve the use of a DAT inhibitor as
a replacement therapy. However, despite an abundance of research, finding or developing a
DAT inhibitor with enough DAT inhibition to convey some cocaine-like behavior without the
high abuse potential of cocaine has proven difficult. Clearly there is more research needed in
order to help in this drug development area. As previously mentioned, the greatest issue with
cocaine dependence treatments is to produce a DAT inhibitor that mimics some cocaine-like
effects, but with limited abuse liability. Given the previously discussed results, plus the
observation that a high affinity DAT inhibitor, like buproprion, has low abuse liability,
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further research into high affinity, selective DAT inhibitors may prove productive for
developing a treatment for cocaine dependence. Although there is a large body of data
showing results of studies with numerous DAT inhibitors, to date very little information is
available about the effects of a selective, high affinity DAT inhibitor. It is thought that
investigating the effects of a very selective, high affinity DAT inhibitor could illuminate what
effects are minimally essential for producing drugs with profiles consistent with those
thought ideal for a cocaine replacement therapeutic, however, until recently no such tool has
been available. To this end, the first section of this dissertation was to characterize the
behavioural effects of a novel, selective DAT inhibitor, D-84, as part of a larger drug
development project.
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BEHAVIOURAL CHARACTERISATION OF A HIGHLY SELECTIVE DAT
INHIBITOR

Introduction
As stated earlier, cocaine abuse and addiction is a persistent, worldwide,
socioeconomic and medical problem and an estimated 1.5 million people are addicted to
cocaine (SAMHSA 2000). Studies have shown that cocaine inhibits the uptake of serotonin,
dopamine and noradrenaline (Reith, Meisler, Sershen, & Lajtha, 1986; Taylor & Ho, 1978),
however, the preponderance of its abuse-related effects are likely attributable to its inhibition
of the DAT (Ritz et al., 1987).
It has been hypothesized that a selective DAT inhibitor may provide an effective
therapy for cocaine dependent individuals, and to this end DAT inhibitors have been
investigated as potential replacement therapies for cocaine abuse (Bergman, et al., 1989; F. I.
Carroll, Howard, et al., 2006; Spealman, Madras, & Bergman, 1989). These drugs possess
several effects thought required for a cocaine replacement pharmacotherapeutic, namely an
ability to occasion the cocaine discriminative stimulus, the ability to reduce cocaine selfadministration, and to have a long duration of activity, however, they also have some
undesirable effects (Birmingham, Nader, Grant, Davies, & Nader, 1998; Nader, et al., 1997;
Wojnicki & Glowa, 1996). It is unknown whether a drug with greater selectivity for the DAT
would have an improved profile. D-84 is an optically active three-hydroxy substituted
piperidine derivative of GBR-12935 (Ghorai et al., 2003), and is, to date, one of the most
selective DAT inhibitors available (NIDA 31254 Broad spectrum analysis). The aim of the
present study was to evaluate the behavioural effects of D-84 in cocaine discrimination and
self-administration assays, and to determine the effects of D-84 on cocaine self11

administration in rats, in order to further evaluate its likely usefulness as a replacement
therapy for cocaine dependency. Drug discrimination and self-administration are assays that
demonstrate the subjective and positive reinforcing effects of compounds, respectively
(Balster, 1991b; Schuster & Johanson, 1974; Thompson & Unna, 1977). An ideal
replacement therapy should likely possess a certain level of cocaine-like activity but with
limited abuse potential. A successful treatment should likely have a slower onset but longer
duration of action compared to cocaine, would partially generalize in discrimination studies
and would be self-administered but at lower maximal levels when compared with cocaine.
Partial to full generalization may predict that the compound is able to produce similar subject
effects as cocaine, which consequentially may palliate cravings of the patient. Similarly, to
promote patient compliance a compound would likely need to be self-administered but
ideally with fewer efficacies (abuse liability) compared to cocaine.

Hypothesis
Evidence has shown that cocaine produces its abuse related effects through inhibition
of the DAT (Ritz, et al., 1987). Many non-selective, high affinity DAT inhibitors have been
investigated for their potential to be used as replacement therapies, but to date none have
proven totally satisfactory (Gorelick, et al., 2004). These non-selective, high affinity DAT
inhibitors generalize to cocaine in discrimination studies and are self-administered. Based on
these observations, and on the knowledge that D-84 is a highly selective DAT inhibitor, I
predict that D-84 will at least partially generalise to cocaine in discrimination studies and will
be self-administered above vehicle control levels, thereby satisfying minimal features
essential as a potential replacement therapy for cocaine dependence.
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Materials and Methods

Subjects
Adult, male, experimentally-naive Long-Evans hooded rats (Harlan Sprague-Dawley,
Indianapolis, IN) were used. Subjects were individually housed in an American Association
of Animal Laboratory Care-accredited facility and given ad libitum food and water. For selfadministration studies, free feeding weights were obtained, and food (Harlan Teklad,
Madison, Wisconsin) was subsequently restricted to 15 g a day until rats achieved a target
weight of approximately 320 g. The rats were maintained at this target weight throughout the
study by adjustments in post-session feedings. For discrimination studies, rats were initially
free fed, and then maintained at 85% of their free feeding weights. Post session feeding was
adjusted to maintain these weights throughout the study.
Studies were approved by the Institutional Animal Care and Use Committee of the
Virginia Commonwealth University and conformed with NIH Guidelines for Care and Use of
Laboratory Animals.

Drug Discrimination Apparatus and Procedure

Rat discrimination studies were conducted in two-lever operant conditioning
chambers (Med-Associates Inc., St. Albans, VT) equipped with a house light and food
dispenser that delivered 45 mg food pellets (Research Diets, Noyes Precision Pellets, New
Brunswick, NJ). Scheduling of pellet deliveries and collection of data were accomplished by
a microcomputer and associated interface (Med-Associates Inc., St. Albans, VT, MED-PC®
IV.
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Drug discrimination training occurred during daily (M-F) 15-min experimental
sessions. The rats were initially trained to press one of two levers under a fixed-ratio 1 (FR 1)
schedule of reinforcement in which each lever press resulted in a pellet delivery. The
response requirement was gradually increased to FR 10. During the next few sessions the rats
were reinforced only for pressing the alternate lever until they pressed reliably under FR 10
scheduling conditions, after which drug discrimination training commenced. Rats were
injected with 10 mg/kg cocaine or saline vehicle i.p., 10 min prior to the start of the session.
For each rat, one lever was designated correct following drug administration and the other as
correct following saline administration. The lever upon which the rats initially acquired the
lever press response was designated as the saline-appropriate lever. All responses on the
inappropriate lever were recorded, but had no programmed consequences. The lever on which
the rats were initially trained and on which they acquired the lever-press response was
designated as the vehicle appropriate lever. Alternation of cocaine and saline injections
proceeded according to a two monthly cycle (Month #1: CSSCS, SCCSC, SCSCS, CSCSC;
Month #2: SCCSS, CSCSC, CSSCC, SCSCS; in which C=cocaine S=saline). Lever pressing
produced pellet delivery only on the injection-appropriate lever for that day. Incorrect presses
reset the response requirement on the correct lever. Substitution tests began once a rat met the
following criteria: 1) the first completed fixed ratio (FFR) occurred on the lever designated
correct on at least eight of ten consecutive sessions; and 2) at least 80% of the total responses
were emitted on the correct lever during those eight sessions. After these initial training
criteria were met, testing could occur twice a week on Tuesdays and Fridays, provided that
the rats completed the FFR on the correct lever during the most recent training drug and
saline sessions; otherwise, a training day was administered. Test sessions were identical to
training sessions except completion of the FR10 contingencies on either lever resulted in
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pellet delivery. Dose-response curves were collected first with cocaine (1-30 mg/kg) before
substitution tests with D-84 (1-42 mg/kg) were conducted.

Self-administration Apparatus and Procedure

Self-administration tests were conducted in operant conditioning chambers housed
inside individual, isolated and ventilated boxes (Med-Associates Inc., St. Albans, VT). The
front wall of each chamber was equipped with two retractable levers with a white stimulus
light above each lever. A 5-w house light and Sonalert® tone generator were located on the
rear wall of the chamber.

Infusion Assembly System

Catheters were constructed from polyurethane tubing (Access Technologies, Skokie,
IL; 0.044” O.D. X 0.025” I.D.). The proximal 3.2 cm of the catheter was tapered by
stretching following immersion in hot sesame oil. The catheters were prepared with a
retaining cuff approximately 3 cm from the proximal end of the catheter. A second larger
retaining cuff was positioned approximately 3.4 cm from the proximal end of the catheter.
Mid-scapula cannula/connectors were obtained from Plastics One (Roanoke, VA). The
cannula/connectors consisted of a threaded plastic post through which passed an “L” shaped
section of 22 gauge stainless steel needle tubing. The lower surface of the plastic post was
affixed to a 2 cm diameter disc of Dacron mesh. During sessions the exposed threaded
portion of the infusion cannula was connected to an infusion tether consisting of a 35 cm
length of 0.40 mm i.d. polypropylene tubing encased within a 30 cm stainless steel spring to
15

prevent damage. The upper portion of the 0.40 polypropylene tubing was connected to a fluid
swivel (Lomir Biomedical, Inc, Quebec, Canada) that was, in turn, attached via 0.40
polypropylene tubing to the infusion syringe.

Surgical Procedure
Following acclimation to the laboratory environment, indwelling venous catheters were
implanted into the right external jugular vein. Surgical anesthesia was induced with a
combination of 50 mg/kg ketamine (KetaThesia, Butler Animal Health Supply, Dublin, OH)
and 8.7 mg/kg xylazine (X-Ject E, Butler Animal Health Supply, Dublin, OH). Rats were
additionally administered 8 mg/kg oral enrofloxacin (Baytril, Bio-Serv, Frenchtown, NJ) for
three days postsurgery. The ventral neck area and back of the rat were shaved and wiped with
povidoneiodine,7.5% (Betadine, Purdue Products L.P., Stamford, CT) and isopropyl alcohol.
The rat was placed ventral side down on the surgical table and a 3 cm incision was made 1
cm lateral from mid-scapula. A second 0.5 cm incision was then made mid-scapula. The rat
was then placed dorsal side down on the operating table and a 2.5 cm incision was made
longitudinally through the skin above the jugular area. The underlying fascia was bluntly
dissected and the right external jugular vein isolated and ligated. A small cut was made into
the vein using an iris scissors and the catheter was introduced into the vein and inserted up to
the level of the larger retaining cuff. The vein encircling the catheter between the two cuffs
was then tied with silk suture. A second suture was then used to anchor the catheter to
surrounding fascia. The distal end of the catheter was passed subcutaneously and attached to
the cannula/connector that was then inserted subcutaneously through the larger incision. The
upper post portion of the connector/cannula exited through the smaller mid-scapula incision.
All incisions were then sprayed with a gentamicin sulfate/betamethasone valerate topical
antibiotic (Betagen, Med- Pharmex, Inc., Pomona, CA) and the incisions were closed with
16

Michel wound clips. Rats were allowed to recover from surgery for at least 5 days before
self-administration training began. Periodically throughout training, methohexital (1.5 mg/kg)
or ketamine (5 mg/kg) (KetaThesia, Butler Animal Health Supply, Dublin, OH) was infused
through the catheters to determine patency as inferred when immediate anesthesia was
induced. Between sessions the catheters were flushed and filled with 0.1 ml of a 25%
glycerol (Acros, New Jersey)/75% sterile saline locking solution containing: 250 units/ml
heparin (Abraxis Pharmaceutical Products, Schaumburg, IL) and 250 mg/ml ticarcillin/9
mg/ml clavulanic acid (Timentin, GlaxoSmithKline, Research Triangle Park, NC). If during
the experiment a catheter was determined to be inpatent, the left external jugular was then
catheterized and the rat was returned to testing.

Pre-treatment Tests with D-84 in Rats Self-administering Cocaine
Cocaine self-administration training sessions were 2 h in duration and were conducted 5
days a week (M-F), unless testing had begun, and then sessions were run continuously until
testing was completed. Initially, each response (fixed ratio 1, FR1) on the right-side lever
resulted in delivery of a 0.5-mg/kg cocaine infusion (0.18 ml/6 sec). For the duration of the
infusion, the tone sounded and the stimulus lights above both levers flashed at 3 Hz. Active
(right-side) lever presses during the infusions as well as all inactive (left-side) lever presses
were recorded but were without scheduled consequences.
Pre-treatment testing began once rats had met the following criteria: no increasing or
decreasing trends in infusion numbers for 3 consecutive sessions had occurred, and the
animals received at least 15 infusions during each session. Once these criteria were met, daily
injections of vehicle were administered i.p. immediately prior to each session in order to
habituate the rats to pre-session injections.
After training criteria were met, a cocaine self-administration dose-effect curve was
17

obtained. Initially, saline was substituted for cocaine for at least three consecutive sessions.
When the number of saline infusions during the third or later session of its substitution was <
50% the number of infusions during the most recent session of cocaine administration, the
rats were returned to 0.5 mg/kg/inf cocaine self-administration. When the number of
infusions of the training dose of cocaine obtained during a session was greater than the
number of saline infusions on the last of its substitution, a new dose of cocaine could then be
substituted. Each dose of cocaine was substituted for one day. Between substitutions the rats
were returned to 0.5 mg/kg/inf cocaine self-administration for at least one session and until
the number of infusions exceeded the number obtained on the last day of saline substitution.
On each cocaine dose test day either vehicle or a dose of a pretreatment test drug was given
before test session start. Pretreatment tests with vehicle preceded those with test compounds.
Pre-treatment’s with cocaine (10 mg/kg) and D-84 (9.6, 17.1 and 30.4 mg/kg) were tested
across the self-administration dose-effect curve of cocaine. Self-administered doses of
cocaine tested included 0.01, 0.1, 0.5 and 1 mg/kg/inf. These self-administration doses were
used based on historical studies performed in the laboratory that the current experiment were
conducted in. The 10 mg/kg cocaine pre-treatment dose was selected based on the training
dose of cocaine for the discrimination studies, and the pre-treatment doses of D-84 were
selected based on ED50 values of D-84 and doses one half log unit higher and lower
determined during a previous mouse cocaine discrimination study (Ghorai et al 2003).

Self-administration of D-84

Once pretreatment studies had been completed, other rats were trained to selfadminister 0.5 mg/kg/inf cocaine in an identical fashion as described for rats used in the
pretreatment study. When neither increasing nor decreasing trends in infusion numbers for 3
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consecutive sessions had occurred, and the rats had obtained at least 15 infusions during each
session, cue changes (stimulus light flashes above levers and Sonalert activations) during
infusions were discontinued. Discontinuation of cue changes were initiated to permit rapid
extinction of lever pressing during substitutions with doses of D-84. After three sessions of
0.5 mg/kg/infuse cocaine self-administration occurred during which neither increasing nor
decreasing trends in infusion numbers occurred, saline was substituted as the available
infusate until the number of infusions obtained during a session was less than 50% the mean
of the most recent three cocaine sessions. Rats were then returned to 0.5 mg/kg/cocaine
availability without cues until trends in infusion numbers did not occur across three
consecutive sessions. Vehicle, and increasing doses of D-84 (0.1, 0.3, 0.56 and 1.0
mg/kg/infusion) were then substituted for three consecutive sessions each. Following tests
with D-84, the rats were returned to 0.5 mg/kg/inf cocaine availability for three consecutive
sessions.

Drugs
Cocaine HCl was obtained from the National Institute of Drug Abuse, and was
dissolved in 0.05% saline. D-84, a 3-hydroxy substituted piperadine analogue of GBR-12935,
was synthesized according to methods described previously (Ghorai et al 2003). D-84 was
solubilized in 20% -cyclodextrin in sterile water. (Cavitron 82003, Cargill Food and Pharma
specialists, Cedar Rapids, IA). During discrimination tests, D-84 was administered i.p 20
minutes before the start of the test session. This pre-treatment time was chosen because
previous locomotor studies indicated that peak effects on locomotor activity occurred at 20
min post-injection. Cocaine was administered 10 minutes before the start of discrimination
studies base on previous cocaine discrimination studies conducted in this laboratory. All
drugs were administered in a volume of 1.0 ml/kg when administered i.p.
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Data Analysis

For drug discrimination studies, the percentage of cocaine-lever responding (% CLR)
was calculated for each subject by dividing the number of lever presses emitted upon the
cocaine lever by the total number of presses emitted upon both levers and multiplying this
quotient by 100. Individual values of % CLR were then averaged (±SEM). Complete
generalization to the cocaine discriminative stimulus was inferred when % CLR was > 80%.
Mean response rates for each test condition were calculated by dividing the total number of
lever presses emitted upon both levers by the session duration (900 s) for each subject, and
then these rates were averaged (±SEM). If a rat failed to make at least ten lever presses
during a test session, its data were excluded from calculations of % CLR but were included
for mean response rate determinations. This exclusion was made to prevent near-zero rates of
responding from disproportionately influencing percent cocaine lever responding. ED50
values and their confidence intervals (CI) were calculated for % CLR and for reducing
response rates using nonlinear regression analysis.
For self-administration substitution studies, data from the last day of substitution at
each dose were used in the analyses. One-way repeated measures ANOVA, followed by
Dunnett’s post hoc tests, were used to compare self-infusions of drug to self-infusions of
saline. For self-administration pretreatment studies, one-way repeated measures ANOVA
were conducted at each dose of cocaine self-administered on cocaine intake (mg/kg/2-h
session). Post-hoc analyses were conducted comparing cocaine intake during pretreatments
with D-84 to vehicle pretreatment within each dose of cocaine self-administered using
Dunnett’s post tests. ED50 values and their confidence intervals (CI) for reducing cocaine
intake were calculated using a variable slope, nonlinear regression analysis. In order to permit
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calculations of ED50 values, a "dose" of 0.96 mg/kg (an order of magnitude lower than the
lowest dose of D-84 tested) was assigned for the vehicle dose. ED50 values were assumed
"incalculable" if their CIs ranged greater than two orders of magnitude. Statistical
significance was assumed in all analyses if p<0.05. Statistical analyses and nonlinear
regressions were performed using GraphPad Prism version 5.0 for Mac OSX, (GraphPad
Software, San Diego, California USA).

Results
Effects of D-84 in Cocaine Discriminating Rats

Cocaine completely generalized to the 10 mg/kg cocaine training dose at doses of 10
and 30 mg/kg with an ED50 (CI) value for producing cocaine-lever responding of 2.85 mg/kg
(2.1-3.5 mg/kg). When saline was tested, near-zero levels of cocaine-lever responding
occurred (Fig. 2, Upper panel). At the highest dose of cocaine tested (30 mg/kg), rates of
responding were decreased by ~50% relative to saline control levels (Fig. 1, lower panel). As
D-84 dose increased, levels of %CLR increased until a maximum of 76% CLR occurred at a
dose of 30.4 mg/kg, a dose which markedly reduced response rates, and complete
generalization to the 10 mg/kg cocaine training dose never occurred (Fig.2 upper panel).
Despite D-84's incomplete generalization to the cocaine stimulus, an ED50 (±CI) was
calculable (8.2 (3.4-19.8) mg/kg).
Cocaine dose-dependently reduced response rates with an ED50 (CI) value of 13.83
(4.8-39.3) mg/kg. D-84 also dose-dependently reduced response rates with an ED50 (CI)
value of 33.9 mg/kg (15-72) mg/kg (Fig.2 lower panel).
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Self-administration of Cocaine and D-84 and the Effects of D-84 Pretreatment on Cocaine Self-Administration in Rats

Fig. 3 (upper panel) shows the mean numbers of infusions obtained when cocaine and
D-84 were available for self-administration. The relationship between self-administered
cocaine infusions and dose was characterized by an inverted U-shaped curve with peak
numbers of infusions occurring at the intermediate cocaine dose of 0.1 mg/kg/infusion, which
was significantly greater than saline control numbers (p<0.05). D-84's self-administration
was also characterized by a U-shaped curve relating infusions to dose with peak numbers of
infusions occurring at 0.3 mg/kg/infusion, and which were significantly greater than vehicle
control numbers (p<0.05). Fig. 3 (lower panel) shows mean drug intake (mg/kg/2-session) of
self-administered cocaine and D-84. Mean drug intake for both cocaine and D-84 increased
as a function of dose. Peak levels of D-84 (21.6±4.61) intake were nonsignificantly lower
than peak levels of cocaine (24.3±3.34) intake.

Effects of D-84 Pre-treatment on Cocaine Intake

Fig. 4 shows the mean cocaine intake (mg/kg/2-h session) obtained following D-84
pretreatment as a function of self-administered cocaine dose. Compared to vehicle
pretreatment, the highest dose of D-84, 30.4 mg/kg, significantly reduced cocaine intake at
cocaine self-administered doses of 0.5 (p=0.0167) and 1.0 (p=0.0254) mg/kg/infusion.
Generally, pre-treatment with low to intermediate doses of D-84 non-significantly decreased
intake of low dose cocaine self-administration.
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Fig. 2. Upper panel: Effects of cocaine and D-84 dose (mg/kg) on the percentage of cocaine lever
responses in rats trained to discriminate 10 mg/kg cocaine. “V”=20% w/v cyclodextrin
vehicle; "S"=saline; filled circles=cocaine; filled squares=D-84. Each symbol represents a mean
of six rats, except N=4 and 2 at 30 and 42 mg/kg, respectively, because some rats failed to
meet minimum response rate criteria (see text) and their data were not included for %CLR
expressions but were included for expressions of response rate. Bars represent ±SEM. When
ratios of N are provided at a dose the denominator indicates total rats tested at that dose, and
the numerator indicates the number meeting response rate criteria. If a rat failed to meet
response rate criteria at a lower dose, it was not tested at higher doses (e.g., only four rats were
tested at 42 mg/kg because two had not met response rate criteria at 30 mg/kg).
Bottom panel: Mean numbers of total lever presses per sec. Each symbol represents a mean
of six rats except N=4 at 42 mg/kg because two rats failed to meet response criteria at the
preceding, lower dose (i.e., at 30 mg/kg) and were not tested at higher doses (see text).
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Fig. 3. Upper panel: Mean infusions of saline (unfilled circles) and D-84s vehicle (unfilled
squares), and of cocaine (filled circles) and D-84 (filled squares) obtained as a function of
dose. Brackets through data points indicate ±SEM. N=5 at all conditions. * = p< 0.05 as
compared to saline; # = p< 0.05 as compared to vehicle.
Bottom panel: Mean drug intake (mg/kg/2-h session) as a function of dose. Other details as
described for the upper panel.
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Fig. 4. Cocaine intake (mg/kg/2-h session) obtained following the various pretreatments as a
function of self-administered cocaine dose. * = p< 0.05 as compared to vehicle pre-treatment.
Bars through data points ±S.E.M.
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Discussion

The objective of the current study was to characterize the behavioural effects of the
selective DAT inhibitor, D-84, a 3-hydroxy-piperazine derivative of GBR-12935 (Ghorai, et
al., 2003), in order to further determine its potential as a replacement therapy for cocaine
dependence. The results showed that D-84 partially generalized to the cocaine discriminative
stimulus, attenuated cocaine self-administration and was self-administered significantly
higher than vehicle control levels.
Previous research has shown that binding potencies of DAT inhibitors correlate well
with their reinforcing effects in self-administration (Ritz et al., 1987), and as a result, research
into replacement therapies for cocaine dependence has focused on DAT inhibitors (F. I.
Carroll et al., 2006; J.L Katz, Kopajtic, Agoston, & Newman, 2003). The fast onset and short
duration of action of psychostimulant drugs likely contribute to their abuse liability, and it is
thought that a replacement therapy with a slower onset and longer duration of action may
compete with and effectively reduce craving for cocaine, but have a lower abuse potential
than cocaine. This theory is based on the successful treatment of treating opiate dependence
with the replacement therapy, methadone (Uchtenhagen, 2003). There have been several
studies evaluating the effectiveness of DAT inhibitors as replacement therapies for cocaineabusing subjects, but so far none have proven unequivocally effective or have had
unacceptable toxicity. GBR-12909 has a high affinity for the DAT and results in non-human
primates showed that it attenuates cocaine self-administration (Stafford, Rice, Lewis, &
Glowa, 2000), however clinical trials were halted during phase I due to cardiac toxicity
(Herman BH et al 2005). It is possible that a more selective DAT inhibitor with less NET
activity may provide the right balance of cocaine-like effects but with reduced toxicity and
therefore provide a usable replacement therapy for cocaine dependence.
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To that end, D-84 was synthesized and subsequently identified as one of the most
selective DAT inhibitors here-to-fore disclosed (Ghorai et al., 2003). In the current study, D84 occasioned incomplete generalization (76%) in cocaine discriminating rats. This is
consistent with previously published data showing that D-84 produces incomplete
generalization (67%CLR) to cocaine in mice (Ghorai et al.,2003). Because in vitro binding
efficacy at the DAT generally correlates well with in vivo efficacy for inhibiting DA uptake,
and corresponding cocaine-like effects, it is surprising that D-84, being a potent and
efficacious DAT inhibitor, did not occasion complete generalization to cocaine’s
discriminative stimulus. There are, however, other DAT compounds that fall into this
category of being selective for DAT over serotonin or norepinephrine, without producing full
generalization. Benztropine is a well known cocaine analogue that binds to the DAT with
similar potency to cocaine but does not produce full generalization in cocaine discrimination
studies (Newman, et al., 1994). It is thought that the decrease in cocaine-like behavioural
effects of benztropine analogues is likely due to the antimuscarinic effects inherent in these
compounds (Ranaldi & Woolverton, 2002). A broad spectrum binding evaluation of D-84
(NIDA Broad Spectrum Analysis 32154) indicated that it has low muscarinic activity (M1
Ki= 512 nM, M2 Ki= 816 nM) that unlikely limited its generalization to cocaine. D-84 also
has activity at D4 receptors (Ki 28.9 nM), but it is difficult to determine how much of an
influence this may have on D-84’s behavioural effects.
A potential cocaine replacement therapy likely needs to share some of the subjective
effects with cocaine, and D-84 does occasion partial cocaine-lever responding (maximum of
76% CLR). D-84's partial generalization to cocaine's discriminative stimulus could translate
into a reduction of craving for cocaine if used as a medication. D-84 was self-administered,
but was less potent than cocaine. Its self-administration suggests it likely would promote
patient compliance. Finally, D-84's ability to reduce self-administration of higher doses of
27

cocaine suggests that it may substitute for cocaine when given as a pretreatment. This latter
suggestion, however, needs qualification somewhat by the observation that D-84 also reduced
food maintained response rates at high doses during discrimination tests, suggesting that
some of the non-specific effects of D-84 could contribute to the attenuation of cocaine selfadministration.
D-84 is less potent but longer acting than cocaine for stimulating locomotor activity in
mice (Ghorai et al., 2003). D-84 is both less potent and efficacious than cocaine in producing
cocaine's discriminative stimulus effects in mice (Ghorai et al., 2003) and in rats (present
study). D-84 was also less potent than cocaine as a reinforcer in the present study.
Considering D-84s general lower potency than cocaine, and observing that D-84 was selfadministered at a lower peak infusion level than cocaine, and at a somewhat lower peak
intake level as well, it seems likely that peak cocaine-like effects were never obtained with D84 during the self-administration tests. Those observations raise the possibility that D-84 has
less reinforcing efficacy, and consequent lower abuse potential, than cocaine. Additional
studies, however, more directly addressing relative reinforcing efficacy between D-84 with
cocaine and other known drugs of abuse (e.g., progressive ratio or choice studies) are needed
to more definitively predict D-84s likely relative abuse potential.

Conclusions
The results of the current study show that D-84 is less potent and efficacious than
cocaine in occasioning cocaine-like subjective effects, maintains self-administration at lower
infusion levels, and can reduce cocaine self-administration when given as a pretreatment.
These results show that D-84 possesses some favourable characteristics likely desirable for a
replacement therapy in treating cocaine dependency, and encourages further study for its
utility as a pharmacotherapeutic.
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The goal of this section of the dissertation was to evaluate the behavioural
characteristics of D-84, a novel selective DAT inhibitor, as a potential drug developmental
candidate. Cocaine’s abuse related effects are attributable to its inhibitory actions at the DAT
(Ritz et al., 1987), and a potential treatment for cocaine dependence could be a DAT inhibitor
with tolerable toxicity. The current results with D-84 are, so far, consistent with that desirable
profile. However, although the discrimination, self-administration, and pre-treatment effects
of D84 seemed favourable, they could be improved upon. Recent evidence has suggested that
the serotonergic system plays a modulatory role in cocaine’s behavioural effects (Xi,
Gardner, 2008).

The second part of this dissertation study focused on this serotonin

component in an attempt to determine whether altering the level of SERT inhibition
modulates the cocaine-like behaviour of high affinity DAT inhibitors. Introducing some
SERT inhibition, to DAT inhibition, could lead to an improved profile as a potential cocaine
replacement therapy, relative to a highly selective DAT inhibitor such as D-84.
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INVESTIGATING THE INFLUENCE OF SERT INHIBITION ON THE
COCAINE-LIKE BEHAVIOURAL EFFECTS OF DAT INHIBITORS

Serotonin –Dopamine Interactions
Selectivity at the DAT is predominantly responsible for cocaine’s strong reinforcing
effects (Ritz, et al., 1987), suggesting that a highly selective DAT inhibitor may have its own
strong reinforcing effects and likely comparable abuse potential. This can be problematic in
terms of developing compounds to act as potential replacement therapies. While it is
advantageous for treatment compounds to share some behavioural effects with cocaine in
order to treat and insure compliance by the patient, a potential treatment needs also to have
less inherent abuse potential than cocaine itself.

Role of Serotonin in Modulating the Reinforcing Effects of Cocaine
Although there is sufficient evidence to support the hypothesis that cocaine produces
its reinforcing effects by stimulating the mesolimbic dopamine pathway, it has other
biochemical effects as well. Cocaine also binds to and inhibits uptake at the serotonin (SERT)
and norepinephrine (NE) transporters (NET) (Koe, 1976; Reith, Sershen, Allen, & Lajtha,
1983). It has generally been determined that binding to NET does not play a major role in the
reinforcing effects of psychomotor stimulants (Wee et al., 2006; Woolverton, 1987; Yokel &
Wise, 1975) and might even have a role in producing the aversive effects of cocaine (Jones,
Hall, Uhl, & Riley, 2010).
The 5-HT system has become implicated in the development of novel
pharmacotherapies for drug abuse and addiction (Xi & Gardner, 2008). Focus has been
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applied to the potential importance of 5-HT in modulating the reinforcing effects of cocaine.
Serotonin (5-HT) neurons originate in the raphe nuclei in the midbrain and project to
numerous other brain regions (Hoyer, Hannon, & Martin, 2002), including the mesolimbic
DA pathway, where activation of 5-HT receptors within this reward pathway has shown to
have a modulating effect on the DA system (Bubar & Cunningham, 2006). It has been
determined that, of the 14 subtypes of 5-HT receptors, the 5-HT2A and 5-HT2C receptor
families play major roles in modulating DA output (Higgins & Fletcher, 2003). It has been
shown that 5-HT2c receptors inhibit mesolimbic DA output, whilst 5-HT2A receptor
activation potentiates it suggesting that a net effect of activation or inhibition could occur
depending on which receptor system has the predominant influence at the moment. Given
the current literature, it seems that the serotonergic system in the brain plays an important
role in modulating the effects of dopamine in the mesolimbic reward system. As further
evidence of the serotonin system's role, it has also been shown that an increase in extra
cellular 5-HT, after administration of the selective serotonin reuptake inhibitor (SSRI),
fluoxetine, has an inhibitory effect on cocaine self-administration (M. E. Carroll, Lac,
Asencio, & Kragh, 1990a; Howell & Byrd, 1995; Peltier & Schenk, 1993; Porrino et al.,
1989). In addition, it has been shown that systemic administration of fluoxetine and 8-OHDPAT, a 5-HT1A agonist, reduces low dose cocaine self-administration (M. E. Carroll, et al.,
1990a; Peltier & Schenk, 1993). Loh and Roberts (1990) trained rats to self-administer
cocaine on a progressive ratio (PR) schedule. Rats were then given intracerebral injections of
the selective 5-HT neurotoxin, 5-7-dihydroxytryptamine. In comparison to sham-treated
control animals, the break point for cocaine self-administration in 5-HT depleted animals was
increased suggesting that decreased levels of brain 5-HT increased motivation for cocaine
self-administration, possibly by altering the incentive value of cocaine (Loh & Roberts,
1990). A further study in squirrel monkeys pretreated with either a 5-HT uptake inhibitor or a
31

direct 5-HT agonist attenuated cocaine self- administration (Czoty, Ginsburg, & Howell,
2002).
Studies involving SSRI’s and direct 5-HT receptor agonists and antagonists have
provided further evidence to document that 5-HT has a dampening effect on cocaine’s
reinforcing effects and that serotonergic compounds themselves have very few cocaine-like
behaviours. Drug discrimination studies with SSRI’s have shown that they do not generalize
to the cocaine discriminative stimulus and are not self-administered, suggesting that these
compounds are not cocaine-like and likely have low abuse liability (Callahan & Cunningham,
1997; Cunningham & Callahan, 1991; Simon & Appel, 1997).
Taken together, these studies point to an important role of 5-HT in modulating the
reinforcing effects of cocaine. Given the lack of reinforcing properties of 5-HT agonists,
combined with the ability of SSRI’s to reduce cocaine’s positive reinforcing effects, it seems
possible that the serotonergic system could be used to modulate the positive reinforcing
effects of cocaine-like compounds in an effort to reduce their abuse potential.
Overall, these research reports indicate that increasing the level of 5-HT uptake
inhibition, resulting in increases of 5-HT at its receptors, tends to decrease the reinforcing
strength of cocaine. This, therefore, introduces the possibility that a DAT inhibitor possessing
an optimum level of SERT inhibition could inherently have a decreased reinforcing efficacy
while still retaining some cocaine-like activity to palliate the cocaine addict.
An added advantage to having increased serotonergic activity is the effect of serotonin
on depression. A major side effect of cocaine withdrawal, and hence one reason for the high
rate of relapse, is depression. If a DAT inhibitor possessed a sufficient level of SERT
inhibition, it may not only reduce the abuse potential of the drug, but also, given the use of
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SSRI’s in the treatment of depression (Hamon, 1995), may help treat the depression seen
upon cessation of cocaine use .
The results reported with D-84 in Chapter Two showed promise of its potential as a
replacement therapy for cocaine. It has a long duration of activity, partially generalizes to
cocaine and is self-administered but maintains rates of responding at levels lower than
cocaine. All of these factors promote its potential as a candidate for drug development.
Having said this, other evidence is available suggesting that other compounds could also be
potential cocaine-dependence treatments. Taking into account all of the evidence currently
available concerning the influence of serotonin on dopamine transmission, and
consequentially on cocaine’s reinforcing effects, it seems plausible that another possible
replacement therapy for cocaine dependence, or an enhanced one, could be a DAT inhibitor
that concurrently possessed an optimum level of SERT inhibition. The DAT component
would allow a compound to retain some cocaine-like behavior, whilst the SERT influence
would dampen the acute reinforcing effects of the compound and at the same time potentially
help in treating depression produced upon withdrawal from cocaine use. Having said this,
there are still many unanswered questions. Not all DAT inhibitors are considered equal, as
discussed earlier, and cocaine is considered to be a triple amine uptake inhibitor that has high
affinity for the SERT as well as the DAT. Obviously, given the positive reinforcing effects of
cocaine, this level of SERT inhibition is clearly not having an inhibitory effect. This may
imply that the level of SERT inhibition, and not the mere presence of SERT inhibition, may
be key in producing a compound that retains some cocaine-like behavior but with enough
SERT inhibition to attenuate abuse liability.
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The aim of the following study was to examine the effects of selective DAT inhibitors
that vary in their level of SERT inhibition, in order to characterize how a change in SERT
inhibition influences the cocaine-like behavioural effects of high affinity DAT inhibitors.

Hypothesis
The central hypothesis of this study is that increasing the level of SERT
inhibition will decrease the cocaine-like effects of DAT inhibitors. The goal of this project
will be completed by fulfilling the following specific aims:

1: Identify individual DAT inhibitors with levels of SERT inhibition that can be identified as
“low” (Ki >1500nM), “medium” (Ki between 70nM - 1500nM) and “high” (Ki <70nM)
SERT inhibitors, and evaluate their effects in locomotor activity to determine how the level
of serotonergic activity affects their locomotor activity.

2: Evaluate the effects of the selected drugs in cocaine discrimination procedures to
determine how the level of serotonergic activity modulates their discriminative stimulus (i.e.,
subjective) and response rate effects.

3: Evaluate the effects of selected DAT inhibitors in self-administration procedures to
identify how serotonergic levels affect self-administration of the test compounds.

Experimental Approach
The immediate objective of the following studies is to evaluate the role of SERT
uptake inhibition in modulating the cocaine like-behavioural effects of DAT inhibitors. In
particular, the goal is to determine if the level of SERT inhibition is regularly related to the
magnitude of cocaine-like activity.
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Three compounds with a similar high DAT uptake potency and efficacy were
identified but which varied in their level of SERT inhibition. Drugs were categorized
according to their level of SERT uptake inhibition. Compounds with SERT Ki values of <
90nM were deemed “high” SERT activity drugs; SERT Ki values between 70-1500 nM were
deemed “medium” SERT activity drugs; and those with Ki values > 1500 nM were deemed
“low” SERT activity drugs. These cut-off values were selected based upon general referrents
to drugs in the relevant scientific literature, but more importantly following consultations
with dissertation committee member, Maarten Reith, Ph.D.

Selection of Test Compounds
Table 1 identifies the compounds tested. The compounds were selected to be as
similar as possible in their DAT inhibition but to vary widely in their level of SERT
inhibition, with the objective of inferring that any differences in behavioural effects would be
due to the influence of SERT inhibition. The compounds were also selected upon having low
and similar levels of NET inhibition to minimize influence by noradrenergic activity.

D-84
D-84 is an optically active 3-hydroxy substituted piperidine derivative of GBR-12935
(Ghorai et al., 2003), and is, to date, one of the most selective DAT inhibitors currently
available (NIDA 31254 Broad spectrum analysis). It has very low affinity for SERT (Ki =
1274 nM), and as such fills the role as a “high DAT, low SERT” compound. Previous
research has shown it to have a similar onset of action in locomotor activity studies but a
longer duration of activity when compared to cocaine (Ghorai, et al., 2003). This same study
also showed incomplete generalisation to cocaine in discrimination tests in mice. Since it has
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been determined that D-84 is a highly selective DAT inhibitor with extremely low SERT
activity, D-84 was chosen as the “low” SERT compound. D-84 was behaviourally
characterised as reported in chapter two, and the results provided information regarding its
potential as a replacement therapy. It was selected as the "high DAT, low SERT" compound
to help aid the objectives of the second section of this dissertation. The data for D-84
presented in this chapter are data that were collected and reported previously (Ghorai, et al.,
2003) and is being presented here for comparison purposes.

GBR-12909
GBR-12909 is a high affinity DAT inhibitor that possesses affinity for the SERT (Ki
DAT= 10.6nM, SERT= 73nM) and, by the rationale described previously, is considered to be
a “medium” SERT inhibitor. Studies have shown that GBR-12909 increases extracellular DA
in rats (Rothman et al., 1989) and pre-treatment with GBR-12909 reduces cocaine induced
increases in extracellular DA (Rothman, et al., 1991). It has also been shown to generalize to
cocaine in discrimination studies (Holtzman, 2001), to be self-administered in rats and nonhuman primates, and shows similar break points to cocaine in progressive ratio studies
(Roberts, 1993). It is also the only drug of the current studies to have been assessed clinically
for its potential as a cocaine dependence treatment (Vocci & Elkashef, 2005). Observing its
level of SERT inhibition, it was selected as the candidate as a "high DAT, medium SERT"
compound for the purposes of these experiments.
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RTI-55
(–)-2β-Carbomethoxy-3β-(4-iodophenyl)tropane (RTI-55,

β-CIT)

is

a

potent

phenyltropane DAT inhibitor (Boja et al., 1991) that also has potent uptake inhibition activity
at the SERT (Ki DAT= 1.6nM , SERT= 3.8nM) (Boja, Mitchell, et al., 1992). RTI-55 is selfadministered by rhesus monkeys and fully substitutes for cocaine in food reinforced
discrimination studies (Weed, Mackevicius, Kebabian, & Woolverton, 1995). Other studies
have shown RTI-55 to have cocaine-like discriminative stimulus effects in rats (Boja, Cline,
et al., 1992; Cline, Terry, Carroll, Kuhar, & Katz, 1992). Since it is established that RTI-55 is
a potent DAT inhibitor which also possesses potent inhibition activity at SERT, it was
selected as the “high DAT, high SERT” compound for the purposes of this study. The uptake
inhibition data for cocaine and the selected test compounds are presented in Table 1.

DAT (nM)

SERT (nM)

NET (nM)

Category

COCAINE

270

180

221

MEDIUM SERT

D-84

4.05

1274

GBR-12909

4.3

73

426

MEDIUM SERT

RTI-55

1.6

3.8

32

HIGH SERT

LOW SERT

Table 1: Uptake Inhibition Activity (Ki (nM)) for Selected DAT Inhibitors. Cocaine and

GBR-12909 (Matecka et al., 1996, Kuhar et al.,1999 Boos et al.,2006), RTI-55 (Boja et al.,
1992), D-84 (NIDA Broad Spectrum Analysis)
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Effects of DAT/SERT Inhibition on Locomotor Activity
Activation of postsynaptic dopamine receptors in the nucleus accumbens elevates
locomotor activity in rodents (Pijnenburg & van Rossum, 1973; Sharp, Zetterstrom,
Ljungberg, & Ungerstedt, 1987). Consequently, since psychomotor stimulants activate
mesolimbic dopamine receptors, it is this action that is thought associated with the
psychomotor stimulant related dose-dependent increases in locomotor activity in rodents
(Wise & Bozarth, 1987).
It was therefore determined that, since the DAT is a major site of action for cocaine, it
may play a necessary role in cocaine-induced locomotor activity (Uhl, Hall, & Sora, 2002).
Studies have shown that acute administration of low to moderate doses of cocaine stimulates
locomotor activity whilst higher doses are shown to decrease distance traveled due to
increases in stereotyped behavior (Nielsen & Scheel-Kruger, 1988; Post, Weiss, Pert, &
Uhde, 1987; Tyler & Tessel, 1979). DAT knockout (KO) mice have been shown to have
higher than normal locomotor activity levels when compared to wild type mice, presumably
due to the higher basal levels of DA. This same study showed that acute administration of
cocaine increased locomotor activity in wild type mice but not in the DAT KO mice (Giros,
Jaber, Jones, Wightman, & Caron, 1996; Sora et al., 1998), possibly because their baselines
levels of DA were already higher than wild type mice making an increase after cocaine
administration difficult to detect. These and other studies provide evidence to show that DAT
inhibition is responsible for cocaine induced locomotor stimulation suggesting that all of the
selected DAT inhibitors may stimulate locomotor activity. Other studies have shown that
stimulation of the serotonergic system does not significantly affect locomotor activity
(Fletcher, Sinyard, & Higgins, 2006; Fletcher, Sinyard, Salsali, & Baker, 2004), which may
mean that increasing SERT inhibition will not have a pronounced effects in this assay, and
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that the locomotor effects ultimately would be attributable to DAT activity. It should be noted
that selection of the test compounds was made with their NET affinity in mind. NE produces
its behavioural effects through activation of adrenergic receptors which are responsible,
amongst other behaviours, for mediating contraction of vascular smooth muscle (Bylund et
al., 1994). It is this action, along with the production of an enhanced QT interval that has lead
to some NE-related cardiotoxicity, which has prevented compounds with pronounced NE
activity from being developed into approved medications (Herman BH et al., 2005, Vocci FJ
et al., 2005). However, developments over recent years have allowed for the production of
compounds with subtype-selective effects, which may potentially help avoid cardio-related
effects

and

have

prompted

NET-driven

medication

developments

for

stimulant

abuse (Kampman et al., 2006; Sofuoglu, Brown, Babb, Pentel, & Hatsukami, 2000).
Locomotor activity determines whether a compound is generally behaviorally-active,
but can also determine other characteristics of test compounds. Since the main aim of this
experiment was to determine how altering the level of SERT effects the cocaine–like
locomotor activity effects of the selected DAT inhibitors, locomotor activity results can
provide valuable information as to how these DAT inhibitors differ from cocaine and indeed,
each other. As mentioned previously, in terms of drug development, an effective therapy for
cocaine dependence would need share some behavioural effects with cocaine, but show
potential for having a lower abuse liability. Cocaine has a fast onset and short duration of
activity thought to maximize its abuse potential, and it likley would be beneficial for
treatment compounds to have a slower onset and longer duration of activity in an attempt to
reduce their abuse liability. Research reports discussed earlier indicated that the serotonin
system can modulate dopaminergic neurotransmission, therefore potentially alterring
locomotor activity. Locomotor activity studies will determine the onset and duration of
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activity of compounds, as well as peak total distance travelled, all of which can be compared
to determine how changing the level of SERT inhibition alters these variables.

Hypothesis
With the understanding of DA’s involvement in locomotion, it therefore seems
reasonable to predict that since direct acting DA agonists stimulate locomotor activity,
compounds that indirectly activate the DA receptors should also stimulate locomotion. Since
it has been shown that cocaine, by inhibiting the DAT, leads to an increase in extracellular
DA, and this in turn leads to stimulant effects on locomotion, it seems reasonable to assume
that other indirectly acting DA agonists, like other DAT inhibitors, will also have a stimulant
effect on locomotion. Based on binding and affinity data for the chosen drugs, the rank order
of DAT inhibition is RTI-55> D-84> GBR-12909> Cocaine. We would predict that RTI-55
will have the greatest stimulant effect on locomotor activity since it has the highest DAT
inhibition activity, however, it may also be possible that, since SERT inhibition has been
shown to have an inhibitory effect on the stimulant-like effects of cocaine, the locomotor
activity effects of these selected DAT inhibitors may vary based on their level of SERT
inhibition. It also remains to be seen whether the level of DAT uptake inhibition has a greater
effect on peak levels of locomotor, duration of action, or both and also whether the ratio of
DAT/SERT inhibition influences locomotor activity.

Materials and Methods
Subjects
Adult, male Swiss-Webster mice weighing 25-35g were used in the locomotor activity
studies. Mice were allowed to acclimate to the vivarium environment one week prior to the
start of testing and were housed five per cage, with continuous access to food (Harlan Teklad,
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Madison, Wisconsin) and water. All mice were drug naïve at the start of the study and did not
have prior experience with the test chambers. The mice were housed in an AAALACaccredited animal facility with a controlled temperature on a 12h light-dark cycle and all
testing occurred during the light component.

Drugs
All drugs were injected i.p in a volume equivalent to 10ml/kg. The vehicle for cocaine
and RTI-55 was sterile saline and the vehicle for GBR-12909 was 40% cyclodextrin in sterile
water (Sigma Aldrich inc). Drugs (doses) tested were cocaine (1,10 and 30 mg/kg), D-84
(3.0, 10, 30, 56 mg/kg), RTI-55 (0.1, 1.0 and 10 mg/kg) and GBR-12909 (1, 30 and 56
mg/kg).

Apparatus and procedure
Locomotor activity tests were conducted in eight, commercially obtained, automated
activity monitoring devices, enclosed in sound and light attenuating chambers (AccuScan
Instruments, Columbus, OH). The interior of each device is divided into two separate 20 x 20
x 30 cm arena’s permitting the independent and simultaneous measurement of two mice.
Sixteen photobeam sensors are spaced 2.5 cm apart along the walls of the chamber and are
used to detect movement.
Mice were injected and immediately placed into the chambers. A separate vehicle
control group was tested during tests with each compound. Tests were 4 h in duration, and
total distance traveled (cm) during each 10 min of the 240 min test session was recorded as
the dependent measure.
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Data Analysis
Data was analyzed using a two-way repeated measures ANOVA (Prism 5, GraphPad
software, San Diego, CA). Post tests were performed using the Bonferroni test comparing
dose to vehicle at each of the 24, 10-min time points. Differences are inferred when P < 0.05.

Results
Cocaine Increases Total Distance Travelled in a Dose Dependent Manner
Figure 5 shows the time course effects of cocaine over the 4 hour duration of the
experiment. The figure shows the first 60 minutes on the left hand portion of the x axis whilst
the remaining 3 hours are summed on the right portion of the x axis. Doses of 10 and 30
mg/kg cocaine produced peak effects of total distance travelled within the first 10 minutes.
This elevation in locomotor activity returns to near vehicle control levels by the 60 minute
time point. When the data was summed across the remaining three hours, cocaine did not
produce a significant increase in total distance travelled (P>0.05) (Ghorai et al., 2003).

D-84 Increases Total Distance Travelled in a Dose Dependent Manner
Figure 6 shows the time course effects of D-84 over the 4 hour duration of the
experiment. Thirty and 56 mg/kg D-84 stimulated locomotor activity with onset of effects
occurring within the first 10 minutes post injection. Activity levels following injection of 30
mg/kg remained elevated throughout this period; when the data was summed over the
remaining 3 hours activity levels were significantly above vehicle throughout. Peak effects
occurred within the last 3 hours, with maximum total distance travelled reaching ~ 3500 cm.
The highest dose of D-84, 56 mg/kg, initially produced increases in locomotor activity but
following 20 minutes post injection, activity levels decreased to vehicle control levels. When
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the 56 mg/kg data was summed over the remaining 3 hours the activity returned to levels that
were elevated significantly above vehicle control levels. Therefore high dose D-84
significantly increased total distance travelled when compared to vehicle control levels (P<
0.05) and had a longer duration of action when compared to cocaine doses that significantly
increased activity.

GBR-12909 Increases Total Distance Travelled in a Dose Dependent
Manner
Figure 7 shows the effects of doses of GBR -12909 on total distance travelled over the
4 hour time course. 30 and 56 mg/kg GBR-12909 stimulated locomotor activity with an onset
of activity at 10 mins and peak effects 20 minutes post injection. After 56 mg/kg GBR12909 levels remained significantly (p<0.05) elevated compared to vehicle control until
approximately 2 hours into the time course, after which activity levels returned to near
vehicle control levels. 1 mg/kg GBR-12909 did not elevate total distance travelled above
vehicle control levels at any point throughout the 4 hour time course. GBR-12909 produced a
maximum level of total distance travelled of approximately 1600 cm which is approximately
50% less than the maximum level produced by cocaine and D-84.

RTI-55 Increases Total Distance Travelled in a Dose Dependent Manner
Figure 8 shows the effects of doses of RTI-55 on total distance travelled over the 4
hour time course. RTI-55, 0.1 mg/kg, did not affect total distance travelled compared to
vehicle at any time point. RTI-55, 1 mg/kg, produced a peak effect (1400 cm total distance
travelled) at 60 minutes and remained elevated, significantly above vehicle (p<0.05) control
for the remainder of the 4 hour time course. 10 mg/kg RTI-55 produced a peak effect (~1500
cm total distance travelled) at 20 minutes, significantly above vehicle control levels (p<0.05),
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but activity returned to near vehicle levels within 30 minutes post injection and remained
comparable to vehicle for the remainder of the 4 hour time course.

Summary of Results
The aim of the current study was to determine the locomotor activating effects of the
selected test compounds. All test compounds increased locomotor activity statistically above
vehicle control levels (p<0.05) but there were differences in the peak level and duration of
action of these increases. All the compounds were behaviourally active. Cocaine has a fast
onset (10 minutes) and short duration of activity (<60 minutes). Cocaine produced a
maximum level of total distance travelled of approximately 3000 cm. D-84 also has a fast
onset of activity, similiar to cocaine, but has a much longer duration of activity and produced
the highest levels of cumulative total distance travelled when compared to the other
compounds tested (~3500 cm). GBR-12909 had a similar onset of activity compared to
cocaine but showed approximately 50% lower peak levels of locomotor activity compared to
cocaine and D-84 (p<0.05 when compared to cocaine and D-84). RTI-55 was the most potent
compound, stimulating locomotor activity at lower doses than the other compounds. RTI-55
also showed the slowest onset of activity and also had the lowest peak activity levels (p< 0.05
when compared to cocaine and D-84). All of the test compounds had duration of activities
longer than cocaine (D-84>RTI-55>GBR-12909>cocaine).
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Figure 5: Effects of Cocaine on Locomotor Activity in Mice: The results show the effects
of cocaine on total distance traveled over a 4 hour time course. Doses of 10 and 30 mg/kg
cocaine produced peak total distance traveled at 10 minutes post injection. Levels remained
elevated, above vehicle control levels, for the first hour of the 4 hour time course. By the 4
hour end point, all levels were returned to vehicle control levels (Ghorai et al., 2003).
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Figure 6: Effects of D-84 on Locomotor Activity in Mice: The graph shows the effects of
D-84 on total distance traveled over a 4 hour time course. Peak effects were seen at ten
minutes post injection, but by one hour doses of 3 and 10 mg/kg did not differ significantly
from vehicle control levels. Doses of 30 and 56 mg/kg D-84 remained elevated above vehicle
control levels (*p< 0.05) throughout the 4 hour time course. (Ghorai et al., 2003)
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Figure 7: Effects of GBR-12909 on Locomotor Activity in Mice: The results show the
effects of cocaine on total distance traveled over a 4 hour time course. Peak effects were seen
at 10 (56 mg/kg) and 20 (30 mg/kg) minutes post injection and effects remained significantly
elevated above vehicle controls levels until the 60 min time point (30 mg/kg). The highest
dose of 56 mg/kg remained significantly elevated throughout the duration of the 4 hour time
course. 1 mg/kg GBR-12909 did not significantly increase total distance traveled at any time
point. (*=p<0.05, **=p<0.01 and ***=p<0.001 when compared to vehicle control using a
repeated measures ANOVA followed by Dunnets post hoc tests).
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Figure 8: Effects of RTI-55 on Locomotor Activity in Mice: The results show the effects
of RTI-55 on total distance traveled over a 4 hour time course. Peak effects occurred at 20
mins (10 mg/kg) and 60 mins (1 mg/kg) post injection. 1 mg/kg produced distance traveled
significantly above vehicle control throughout the 4 hour time course. RTI-55, 10 mg/kg,
returned to near vehicle levels by the 60 minute time point. 0.1 mg/kg did not significantly
increase distance travelled above vehicle control at any time point.
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Discussion
The overall aim of this experiment was to determine how changing the level of SERT
inhibition influences the locomotor activity effects of the selected DAT compounds. Cocaine
is considered to be a triple amine uptake inhibitor and is not selective for the DAT over the
other monoamine transporters (Koe, 1976; Reith, et al., 1983). Cocaine stimulated locomotor
activity, increasing total distance travelled in a dose dependent manner (Ghorai et al., 2003).
It has a fast onset (10 minutes) and a relatively short duration of activity (~60 mins), both of
which are thought to contribute to its high abuse liability (Volkow et al., 2000). D-84 is one of
the most selective DAT inhibitors currently available (NIDA Broad Spectrum Analysis) and was
shown to have a fast onset but a very long duration of activity when compared to cocaine. It produced
dose dependent increases in total distance travelled that were statistically greater than vehicle control
but these increases were non-significantly higher than the increases seen with cocaine. The hypothesis
stated that the presence of SERT would decrease cocaine-like behavior. Results with D-84, which
possesses very little SERT inhibition, may support this hypothesis since D-84, while non
significant, exhibited a trend towards a higher stimulation than cocaine and had a much longer

duration of action. If the hypothesis was correct, then the lack of SERT inhibition present in
D-84 may be responsible for this trend towards greater motor stimulating effects of D-84
when compared to cocaine.
GBR-12909 has a high affinity for the DA transporter but also has intermediate
potency at blocking the 5-HT transporter (Andersen, 1987). GBR-12909 had a similar onset
of activity to cocaine but produced lower peak activity effects and had a longer duration of
activity when compared to cocaine. This may support the hypothesis that increased SERT
produces an inhibitory influence on DA neurons that leads to decreased firing and to a
decrease in extracellular DA (Bubar & Cunningham, 2006; Higgins & Fletcher, 2003). A
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decrease in extracellular DA may be responsible for the lower peak activity levels seen with
GBR-12909. These results may further support the hypothesis that SERT inhibition may be
playing an inhibitory role resulting in a decrease in the cocaine-like stimulant effects of the
DAT inhibitor.
RTI-55 has the highest level of DAT inhibition but it also has the highest level of
SERT inhibition compared to the other tested compounds (Boja, Mitchell, et al., 1992). It
showed the lowest peak activity and the slowest onset of activity. RTI-55 produces peak
effects approximately 50% lower than cocaine’s peak effects. A high SERT inhibition will
cause a greater increase in extracellular 5-HT, which could lead to inhibitory effects on
dopamine neurotransmission (Czoty, et al., 2002). RTI-55 also showed an extremely long
duration of activity (greater than 4 hours) compared to cocaine. The duration of activity,
however, could be related to its dissociation from the DAT itself. Cocaine has a fast onset and
offset of activity which is attributable to its fast association and disassociation from the DAT
(Desai, Kopajtic, French, Newman, & Katz, 2005), and it is this action that is thought to be
responsible for producing its robust behavioural effects. RTI-55 is a higher affinity DAT
compound which may disassociate at a slower rate than cocaine, therefore producing its
longer duration of action. The same could be said of all the DAT compounds tested since
they, similarly, all have a longer duration of action than cocaine. Because it is thought that a
slower onset of action of psychomotor stimulants may contribute to a lower abuse potential
(Gorelick, 1998), the slower onset of RTI-55, combined with its longer duration of action,
and lower peak locomotor activating effects, could be advantageous in terms of considering it
a potential cocaine replacement therapy.
The serotonergic system consists of large family of 5-HT receptor subtypes that can
modulate DA neurotransmission and, in particular, it has been shown that the 5-HT2A and 550

HT2C receptor families play a key role in modulating the in vivo activity of psychomotor
stimulants such as cocaine (Bubar & Cunningham, 2006). The serotonergic system is ideally
placed in the CNS to be able to provide a modulatory influence over the DA system (Halliday
& Tork, 1989) and it has been shown that stimulation of 5-HT receptors can change the firing
rate of some DA neurons. Recently, in vitro studies have shown that activation of 5-HT2
receptors can tonically inhibit firing of DA neurons (De Deurwaerdere, Navailles, Berg,
Clarke, & Spampinato, 2004). These and other studies provide evidence to show that SERT
inhibition can influence cocaine-like behavioural effects. The current results showed a
correlation between increasing SERT inhibition and decreased peak locomotor activating
effects. There was no such correlation between increased SERT inhibition and onset and
duration of activity suggesting that these attributes may be unrelated to the presence of
inhibitory SERT effects.

Conclusions
The aim of this experiment was to determine how increasing the level of SERT
inhibition could alter cocaine-like locomotor effects. Increasing the level of SERT inhibition
coincided with a decrease in peak locomotor activity levels. Given that all test compounds
had very similar uptake inhibition affinities at the DAT but differed widely in their level of
SERT inhibition, it can be speculated that this decrease in peak locomotor activating effect is
directly related to modulation by the serotonergic system. Having said that, these differences
in SERT inhibition may not be the only factor contributing to these behavioural activities. As
mentioned earlier, DAT occupancy and binding kinetics could be playing a role, and although
the compounds have similar, low affinities at NET compared to DAT and SERT, this
potential influence on locomotor activity must be taken into account as well.
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As previously mentioned, the goal of these experiments was to determine how
increasing SERT affects the cocaine-like effects of high affinity DAT inhibitors. Locomotor
stimulating effects are one effect of psychomotor stimulants, including cocaine (Tyler &
Tessel, 1979). Cocaine and other psychomotor stimulants also produce discriminative
stimulus effects (Callahan, De La Garza, & Cunningham, 1997), and drug discrimination is
another paradigm for determining how increasing SERT may alter cocaine-like behavior.
Therefore, the next study employed cocaine discrimination procedures to determine if
increasing SERT inhibition affected the way the test compounds generalized to cocaine.
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Effects of DAT/SERT Inhibitors in Cocaine Discriminating Rats

Psychomotor Stimulants and Drug Discrimination

Drug discrimination is a procedure that was developed as a means of assessing
receptor mediated effects and potency of psychomotor drugs (Overton, 1977). It also was
used to make inferences regarding the subjective effects of drugs and their abuse liability
(Rosecrans, 1989; Stolerman, Mariathasan, & Garcha, 1991).
Two discrimination procedures that have been most widely used are the T-maze task
and lever selection in a two lever operant choice procedure (Balster, 1991b). Using these
procedures, the drug acts as an interoceptive stimulus that acquires control over a subject's
responding. Animals are trained to respond appropriately according to the type of stimulus,
drug or vehicle, presented to them prior to the start of the session. For example, Overton et
al., (1961) trained animals to move to the correct side of an elevated T-maze in order to
received food reinforcement contingent upon whether they were pretreated with a training
drug or its vehicle. Animals can also be trained to lever press under intermittent schedules of
reinforcement reinforced with food presentation in operant chambers (Appel et al., 1991;
Balster, 1991a; Callahan, Bryan, & Cunningham, 1995). In this particular paradigm, the
operant chamber has two levers, one designated as the drug lever and the other designated as
the vehicle lever. During any given experimental session pressing only one lever is
reinforced. The animal receives a drug or vehicle injection prior to the start of the session,
and throughout the session only pressing one of the two levers will be reinforced. Pressing
the vehicle lever, after a pre-session vehicle injection, indicates that the animal perceives the
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vehicle effect as different from the drug effect. The percentage of drug lever responding
(%DLR) indicates the degree of similarity between test drugs and the training stimulus. The
response rate variable (RR) measures non-specific behavioural effects of the test compound.
Once animals are reliably trained to select injection-appropriate levers the animals can
be tested using generalization tests. The animal is administered vehicle or any other dose of
training drug or any dose of another drug. If the animal selects the drug lever, it is inferred
that a stimulus generalization occurred between the effects of the test drug with those of the
training drug. If the test drug evokes primarily vehicle-lever selection, then it is inferred that
the test drug did not produce a stimulus that is qualitatively similar to the training drug (it did
not produce stimulus generalization). Tests conducted with doses of the same training drug
but at lower doses show generalization to occur in an orderly, dose-dependent fashion.
Generalisation studies are therefore an effective method of determining how “training druglike” test compounds are.

Cocaine’s Discriminative Stimulus
Cocaine’s discriminative stimulus effects have been studied for years (Jarbe, 1978)
and the involvement of the dopaminergic system in cocaine’s discriminative stimulus effects
has been recognized for some time (Callahan, Appel, & Cunningham, 1991; Johanson &
Fischman, 1989; Witkin, Nichols, Terry, & Katz, 1991) .

Studies with agonists and

antagonists have shown the involvement of the dopamine receptors D1 and D2 in producing
cocaine’s discriminative stimulus effects (Callahan, De la Garza, & Cunningham, 1994; Filip
& Przegalinski, 1997; Witkin, et al., 1991), and it has been shown that lesioning the
dopamine system with 6-hydroxy-dopamine decreasing extracellular DA attenuates cocaine’s
discriminative stimulus effects (Dworkin & Smith, 1988). Substitution tests with dopamine
reuptake inhibitors such as bupropion and mazindol have shown complete substitution for
54

cocaine’s discriminative stimulus (L. E. Baker, Riddle, Saunders, & Appel, 1993; Broadbent,
Michael, Riddle, & Apple, 1991; Witkin, et al., 1991). Further studies have shown that
agonists for D1, D2 and D3 receptors all produce partial to full generalization to cocaine in
discrimination studies (Acri et al., 1995; Callahan & Cunningham, 1993; Kantak, Edwards, &
Spealman, 1995; Terry, Witkin, & Katz, 1994). It has also been shown that D1 and D2
receptor antagonists attenuate the discriminative stimulus effects of cocaine (L. E. Baker, et
al., 1993; Callahan & Cunningham, 1993; Callahan, et al., 1994). These, and other studies,
provide evidence for the role of DA in producing cocaine’s discriminative stimulus cue.

Serotonergic Modulation of Cocaine’s Discriminative Stimulus Effects
There is evidence indicating that SERT inhibition may play a minor role in cocaine
discrimination. It is known that the raphe nuclei of the midbrain possess the 5-HT neurons
that project to the forebrain including the DA mesolimbic system (Vertes, 1991). It has
already been discussed that cocaine’s behavioural effects are chiefly mediated through the
DA mesolimbic pathways, but it should also be noted that the VTA and NA, within this
system, receive input from 5-HT neurons suggesting a possible interaction between the
serotonergic and dopaminergic systems (Gervais & Rouillard, 2000).
Studies have shown that selective reuptake inhibitors for 5-HT and NE do not
generalize to the cocaine discriminative stimulus cue (L. E. Baker, et al., 1993; Callahan &
Cunningham, 1995; Cunningham & Callahan, 1991; Spealman, 1995) but may play a
modulatory role. Although fluoxetine, a SERT inhibitor, fails to generalize to cocaine, it
enhances sub-threshold doses of cocaine, causing a leftward shift in the cocaine doseresponse curve (Callahan & Cunningham, 1997) . This study also showed that agonists at 5HT1A receptors fail to substitute for the cocaine stimulus suggesting that this subtype of 5-HT
receptor may not play a role in the discriminative stimulus effects of cocaine.
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Further studies have shown that manipulation of the 5-HT2 receptor family can
modulate cocaine discrimination. Serotonin 5-HT2 agonists do not themselves mimic the
cocaine cue (Callahan & Cunningham, 1995; Peltier & Schenk, 1993). However, when the 5HT2C/1B receptor antagonist, m-chlorophenylpiperazine (MCPP), is administered in
combination with cocaine, the discriminative stimulus effects of cocaine are attenuated and a
rightward shift in the cocaine dose response curve is produced (Callahan & Cunningham,
1995). MCPP produces its effects primarily through the 5-HT2C receptor as opposed to the 5HT1B receptor (Conn & Sanders-Bush, 1987; Prisco, Pagannone, & Esposito, 1994),
implicating a role for the 5-HT2C receptor in the modulation of cocaine’s discriminative
stimulus effects. There is further evidence to suggest a role for the 5-HT2C receptor system in
modulating cocaine-like discrimination effects. Filip and colleagues showed that local
infusion of a 5-HT2C agonist enhances the discriminative stimulus effects of low dose cocaine
whilst infusion of a 5-HT2C antagonist dose dependently attenuates cocaine-like
discriminative stimulus effects (Filip, Bubar, & Cunningham, 2006). These, and other studies
provide evidence to suggest that the serotonergic system plays a modulatory role in cocaine’s
discriminative stimulus effects and shows the possibility of manipulating this systeme for
advantages in developing compounds for treating cocaine dependence.
Several DAT inhibitors, while retaining some cocaine-like effects, do not possess
effects predictive of a high abuse potential as seen with cocaine (Ferragud, et al., 2009; J. L.
Katz et al., 2001; J.L Katz, et al., 2003). The reasons for this remain unresolved but one
possible explanation is the binding activity of DAT compounds at sites other than the DAT.
Considering serotonin may have an inhibitory influence over DA neurotransmission
(Callahan & Cunningham, 1995), it may be plausible that one possible reason for the lack of
robust reinforcing effects seen with certain DAT compounds could be due to an inhibitory
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SERT component. It remains to be seen if there is a specific or optimum level of SERT
inhibition required to reduce cocaine-like discriminative stimulus effects of DAT compounds
and the goal of this experiment was to determine how increasing the level of SERT inhibition
alters generalization of the test drugs to cocaines discriminative stimulus.

Hypothesis
DA plays a major role in the discriminative stimulus effects of cocaine (Johanson &
Fischman, 1989) but it has also been shown that some DAT inhibitors incompletely
generalize to cocaine in discrimination studies (J.L Katz, et al., 2003). With these
observations in mind, it would be expected that the DAT test compounds may, at least
partially, generalize to cocaine in discrimination studies. However, since it is also known that
serotonin can produce attenuating effects on cocaine discrimination (Callahan &
Cunningham, 1997), it is possible that increasing the level of SERT inhibition will decrease
the cocaine-like discriminative stimulus effects produced by the test compounds.

Experimental Approach
In order to determine how altering the level of SERT inhibition affects generalization
to cocaine, test dose response curves of cocaine, D-84, GBR-12909 and RTI-55 in rats
trained to discriminate 10 mg/kg cocaine from saline in a two lever, food reinforced operant
task were obtained. ED50’s for cocaine lever responding and for reducing response rates
were calculated along with percent cocaine lever selection (%CLR), which was used to
determine generalization to cocaine’s discriminative stimulus. Complete generalization was
inferred when %CLR > 80%.
A change in species were used between locomotor activity and drug discrimination
studies. Mice were used in locomotor studies because the lab had already an established
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database of compounds, pharmacologically similar and dissimilar to the selected test
compounds, to which the current data could contribute or be compared to. Rats were used in
the discrimination studies to facilitate interpretation of data between discrimination and selfadministration studies, and to help determine doses to be tested in self-administration
experiments.

Materials and Methods
Subjects
Adult, male, experimentally-naive Long-Evans hooded rats (Harlan Sprague-Dawley,
Indianapolis, IN) were used. Subjects were individually housed in an AAALAC accredited
animal facility and given ad libitum food and water. Free feeding weights were obtained, and
food (Harlan Teklad, Madison, Wisconsin) was subsequently restricted and rats were then
maintained at 85% of their free feeding weights. Post session feeding was adjusted to
maintain these weights throughout the study.
Studies were approved by the Institutional Animal Care and Use Committee of the
Virginia Commonwealth University and conformed with NIH Guidelines for Care and Use of
Laboratory Animals.

Drug Discrimination Apparatus and Procedure
Rat discrimination studies were conducted in two-lever operant conditioning
chambers (Med-Associates Inc., St. Albans, VT) equipped with a house light and food
dispenser that delivered 45 mg food pellets (Research Diets, Noyes Precision Pellets, New
Brunswick, NJ). Scheduling of pellet deliveries and collection of data were accomplished by
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a microcomputer and associated interface (Med-Associates Inc., St. Albans, VT, MED-PC®
IV).
Drug discrimination training occurred during daily (M-F) 15-min experimental
sessions. The rats were initially trained to press one of two levers under a fixed-ratio 1 (FR
1) schedule of reinforcement in which each lever press resulted in a pellet delivery. The
response requirement was gradually increased to FR 10. During the next few sessions the rats
were reinforced only for pressing the alternate lever until they pressed reliably under FR 10
scheduling conditions, after which drug discrimination training commenced.

Rats were

injected with 10 mg/kg cocaine or saline vehicle i.p., 10 min prior to the start of the session.
For each rat, one lever was designated correct following drug administration and the other as
correct following saline administration. The lever upon which the rats initially acquired the
lever press response was designated as the saline-appropriate lever. All responses on the
inappropriate lever were recorded, but had no programmed consequences. The lever on which
the rats were initially trained and on which they acquired the lever-press response was
designated as the vehicle-appropriate lever. Alternation of cocaine and saline injections
proceeded according to a two-monthly cycle (Month #1: CSSCS, SCCSC, SCSCS, CSCSC;
Month #2: SCCSS, CSCSC, CSSCC, SCSCS; in which C=cocaine S=saline). Lever pressing
produced pellet delivery only on the injection-appropriate lever for that day. Incorrect presses
reset the response requirement on the correct lever.
Substitution tests began once a rat met the following criteria: 1) the first completed
fixed-ratio (FFR) occurred on the lever designated correct on at least eight of ten consecutive
sessions; and 2) at least 80% of the total responses were emitted on the correct lever during
those eight sessions. After these initial training criteria were met, testing could occur twice a
week, on Tuesdays and Fridays, provided that the rats completed the FFR on the correct lever
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during the most recent training drug and saline sessions; otherwise, a training day was
administered. Test sessions were identical to training sessions except completion of the FR10
contingencies on either lever resulted in pellet delivery. Dose-response curves were collected
first with cocaine (1-30 mg/kg) before substitution tests with D-84 (1-42 mg/kg), GBR-12909
(1-30 mg/kg) and RTI-55 (1-30 mg/kg) were conducted.
Drugs
All drugs were injected i.p in a volume equivalent to 1 ml/kg. The vehicle for cocaine
and RTI-55 was sterile saline, and the vehicle for GBR-12909 was 40% cyclodextrin (Sigma
Aldrich, St Louis, MO).
Data Analysis
The percentage of cocaine-lever responding (% CLR) was calculated for each subject
by dividing the number of lever presses emitted upon the cocaine lever by the total number of
presses emitted upon both levers and multiplying this quotient by 100. Individual values of %
CLR were then averaged (+ SEM). Complete generalization to the cocaine discriminative
stimulus was inferred when % CLR was > 80%. Mean response rates for each test condition
were calculated by dividing the total number of lever presses emitted upon both levers by the
session duration (900 s) for each subject, and then these rates were averaged (+SEM). If a rat
failed to make at least ten lever presses during a test session, its data were excluded from
calculations of % CLR but were included for mean response rate determinations. This
exclusion was made to prevent near-zero rates of responding from disproportionately
influencing percent cocaine lever responding. ED50 values and their confidence intervals (CI)
were calculated for % CLR and for reducing response rates using nonlinear regression
analysis (Prism 5, GraphPad software, San Diego, CA).
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Results
Cocaine Fully Generalizes to itself in a Dose Dependent Manner
Cocaine fully generalized to the 10 mg/kg cocaine training dose at doses of 10 and 30
mg/kg with an ED50 (CI) value for producing cocaine-lever responding (CLR) of 2.85 mg/kg
(2.1-3.5 mg/kg). When saline was tested, near-zero levels of CLR occurred. The lowest dose
of cocaine tested, 1.0 mg/kg, occasioned low levels (< 20%) of % CLR (Figure 1, Upper
panel). At the highest dose of cocaine tested (30 mg/kg), rates of responding were decreased
by ~50% relative to saline control levels (Figure 1, lower panel). Cocaine dose-dependently
reduced response rates with an ED50 (CI) value of 13.83 (4.8-39.3) mg/kg. These results
were presented graphically in Chapter 2.

D-84 Produces Incomplete Generalization to Cocaine
As D-84 dose increased, levels of %CLR increased D-84 (ED50 (CI) = 8.2 (3.4-19.8)
mg/kg), but only occasioned a maximum of 76% CLR at a dose of 30.4 mg/kg, and never
produced complete generalization to the 10 mg/kg cocaine training dose (Fig.1 upper panel).
D-84 also dose-dependently reduced response rates with an ED50 (CI) value of 33.9 mg/kg
(15-72) mg/kg (Fig.1 lower panel). These results were presented graphically in Chapter Two.

GBR-12909 Produces Complete Generalization to Cocaine
GBR-12909 completely generalized to the cocaine training dose of 10 mg/kg. GBR12909 (30 mg/kg) produced 98% generalization to cocaine with an ED50 value (CI) for
producing cocaine lever responding of 9.02 mg/kg (4.1-19.8 mg/kg). When vehicle was
tested, near zero levels of % CLR occurred (Fig 9. Upper Panel). The highest dose of GBR-
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12909 tested (30 mg/kg) caused non-significant reductions in response rates (Fig 9. Lower
Panel)

RTI-55 Produces Complete Generalization to Cocaine
RTI-55 fully generalized to the training dose of cocaine.

RTI-55 (10 mg/kg)

produced 82.6% generalization to cocaine with an ED50 value for producing % CLR of
approximately 1.3 mg/kg. When vehicle was tested, near zero levels of CLR occurred (Fig
10. Upper Panel). RTI-55 dose dependently reduced response rates with an ED50 (CI) value
of 5.97 mg/kg (3.26-10.92 mg/kg) (Fig.10 Lower Panel). RTI-55 resulted in a left-ward shift
in the dose response curve when compared to cocaine.
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Fig 9. Upper panel: Effects of cocaine and GBR-12909 dose (mg/kg) on the percentage of cocaine
lever responses in rats trained to discriminate 10 mg/kg cocaine. “V”= 40% cyclodextrin vehicle; “S”
= saline; filled circles= cocaine; filled squares = GBR-12909. Each symbol represents a mean
of six rats. Bars represent ±SEM. Bottom panel: Mean numbers of total lever presses per sec.
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Fig 9. Upper panel: Effects of cocaine and RTI-55 dose (mg/kg) on the percentage of cocaine lever
responses in rats trained to discriminate 10 mg/kg cocaine. “V”= sterile saline vehicle; “S” = saline;
filled circles= cocaine; filled squares = RTI-55. Each symbol represents a mean of six rats except at
the 30 mg/kg dose of RTI-55 where % CLR represents 1 of 4 rats tested (see data analysis text for
explanation). Bars represent ±SEM. Bottom panel: Mean numbers of total lever presses per sec.
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Discussion
Cocaine was shown to completely generalize to itself in these discrimination studies,
with an ED50 value of 2.85 mg/kg. Reductions in response rates were seen with the highest
dose tested. D-84 failed to show complete generalization in these studies. D-84 produced a
maximum of only 76% CLR, which is consistent with previously published results showing
incomplete generalization (67%) to cocaine in mouse discrimination studies (Ghorai, et al.,
2003).
It has been suggested that SERT inhibition may attenuate cocaine-like behavioural
effects of compounds (Callahan & Cunningham, 1997), but it is known that D-84 has little
SERT inhibition activity (NIDA Broad Spectrum Analysis). Given that D-84 has little SERT
inhibitory effects, it is likely that its lack of complete cocaine-like discriminative stimulus
effects has little to do with a SERT modulatory component.
There are a number of DAT inhibitors available that have a high selectivity for the
DAT, generalize to cocaine in discrimination studies, and yet likely possess a much lower
abuse potential than cocaine itself (Bergman, Kamien, & Spealman, 1990; Ferragud, et al.,
2009; J. L. Katz, et al., 1997). Psychomotor stimulants, like cocaine, are known to have a fast
onset of activity which is thought to contribute to their abuse liability (Balster & Schuster,
1973; Kimmel, et al., 2007). There has also been a significant correlation between the
subjective high reported following cocaine administration and high DAT occupancy levels
(Volkow et al., 1997). D-84 may produce a lower DAT occupancy level, when compared to
cocaine, which could be contributing to its lack of full generalization to cocaine in these
discrimination studies. Further studies, possibly with PET neuro-imaging to determine DAT
occupancy after D-84 administration, are needed to further investigate the lack of full
generalization seen with of D-84.
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GBR-12909 is considered, for the purposes of this study, to be an intermediate SERT
uptake inhibitor. It produced full generalization to cocaine (98%) with an ED50 (CI) for
occasioning cocaine-lever responding of 9 mg/kg (4.1-19.8 mg/kg). Response rates were not
significantly reduced at any dose tested. These data confirm previously published studies that
show GBR-12909 generalises to cocaine in discrimination studies (Cunningham & Callahan,
1991; Holtzman, 2001; Spealman, 1993). It may be possible to conclude that since both of
these compounds have similar, intermediate SERT inhibition, that it is not surprising to see
that both compounds produced similar generalization levels, although, based on ED50 values
for occasioning cocaine lever responding, cocaine is more potent than GBR-12909.
RTI-55 is a high affinity DAT inhibitor which also possess high affinity for the SERT
(Boja et al., 1990). RTI-55 produced full generalization to cocaine (83%) with an ED50 for
occasioning cocaine-lever responding of 1.3 mg/kg. RTI-55, however, also produced robust
decreases in rates of responding that may also be attributable to its serotonergic activity.
When comparing maximum % CLR, a trend towards decreasing cocaine-like effects
as the level of SERT inhibition was increased occurred. When increasing the SERT inhibitory
component, a drop in % CLR from 100% with cocaine (SERT Ki 304nM) to 98% with GBR12909 (SERT Ki 4.3 nM) to 82% with RTI-55 (SERT Ki 3.8nM) occurred. Since the test
compounds are similar in their level of DAT inhibition but differ in their level of SERT
inhibition, it may be speculated that this downward trend is attributable to the increased
serotonergic presence. This could possibly be examined by using 5-HT receptor antagonists
to block serotonergic effects to determine how much generalization each DAT compound
produces in the absence of the SERT inhibitory component. However, it also needs to be
noted that the results produced with D-84 complicate this interpretation. D-84 is a novel,
selective DAT inhibitor with very little SERT inhibitory presence. If the presence of SERT
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inhibition was the only possible determinant for producing a decrease in cocaine
generalization with compounds with high DAT inhibition, then it would be expected that D84 would have occassioned complete generalization but didn't. Since the differences in
generalization are not large, it is not possible to determine, from these data, what level of
SERT, if any, is required to produce a complete attenuation of cocaine-like effects.

Conclusions
The goal of this experiment was to determine how an increase in SERT inhibition
would affect the cocaine-like discriminative stimulus effects of the selected compounds.
Although the magnitude of thsis effect wasn’t as robust as expected, a general trend in
decreased cocaine-like discriminative stimulus effects as the level of SERT inhibition was
increased did occur. Since GBR-12909 and RTI-55 had similar activity at DAT, but differed
in their level of SERT inhibition, one possibility is that this decrease in cocaine-like effects is
due to the increased presence of serotonin producing an inhibitory effect on the DA system.
The results with D-84, however, indicate that multiple mechanisms may operate to put limits
on the maximum level of % CLR obtained.

Rats and non-human species can be trained to reliably self-administer cocaine and
other psychomotor stimulants and the final set of experiments focuses on self-administration
in rodents. The overall goal in these subsequent studies was to determine how increasing the
level of SERT inhibition alters levels of self-administration of the selected compounds.
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The Influence of SERT Inhibition on the Self-administration of High
Affinity DAT Inhibitors

It was first reported in the 1960’s that rats and non-human primates surgically
implanted with catheters would self-administer a variety of drugs, including stimulants,
opioids and alcohol (Deneau, Yanagita, & Seevers, 1969; Thompson & Schuster, 1964;
Weeks, 1962). Animals reliably self-administer drugs that are commonly abused by humans
(Johanson & Balster, 1978) and drug self-administration procedures in rodents and nonhuman primates have proven to be productive procedures for investigating the abuse liability
of drugs (Balster, 1991b; Schuster & Johanson, 1974; Thompson & Unna, 1977).
During drug self-administration preparations, animals are implanted with indwelling
venous catheters through which infusions of drugs can be delivered. Delivery of drug is
dependent on the number and pattern of responses which, in part, is determined by the
schedule of reinforcement and the availability of drug.
It has been demonstrated that cocaine is reliably self-administrated in rodents and
non-human primates and that this positive reinforcing effect is, principally, due to its binding
activity at the DAT, resulting in an increase in extracellular DA (Kuhar, Ritz, & Sharkey,
1988; Ritz, et al., 1987; Woolverton & Johnson, 1992). The role of DA in the selfadministration of cocaine is further established by studies using DA receptor ligands. It has
been shown that high efficacy selective D1 agonists readily substitute for cocaine in rats and
rhesus monkeys trained to self-administer cocaine (Self & Stein, 1992; Weed & Woolverton,
1995) and, to further confirm a role of DA in the self-administration of cocaine, it has been
shown that when D1 and D2 antagonists are given as a pretreatment to animals selfadministering cocaine, a rightward shift in the cocaine dose-response curve results, possibly
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implying a decrease in the reinforcing effects of cocaine, or at least its potency (Bergman, et
al., 1990).
The self-administration of synthesized DAT inhibitors has also been investigated
(Howell, et al., 2007; Howell, et al., 2000; Tella, et al., 1997). For instance, RTI-336, a
tropane analogue, is self-administered by rhesus monkeys at rates lower than responding
maintained by cocaine (Howell, et al., 2007). These doses of RTI-336 that reliably
maintained responding, also dose-dependently reduced cocaine self-administration when
given as a pretreatment. GBR-12909, another DAT inhibitor, is reliably self-administered
(Roberts, 1993; Tella, 1995) and has been shown to reduce cocaine self-administration in
rhesus monkeys (Woolverton, Hecht, Agoston, Katz, & Newman, 2001). Benztropine and its
analogues are potent DAT inhibitors, and they too are self-administered, although at lower
levels than cocaine (Hiranita, et al., 2009; Woolverton, et al., 2001).
The above studies suggest a role for the DA system in the reinforcing effects of
cocaine. However, there is evidence to suggest that the serotonergic system may play a
modulatory role in the self-administration of cocaine as well (Walsh & Cunningham, 1997),
possibly by having an inhibitory effect on DA neurotransmission (Alex & Pehek, 2007).
Studies in non-human primates have demonstrated that SERT inhibitors can attenuate the
reinforcing effects of cocaine. The SSRI’s fluoxetine, alaproclate and clomipramine are not
self-administered, and when fluoxetine is given as a pre-treatment it dose-dependently
decreases cocaine self-administration in squirrel monkeys (Howell & Byrd, 1995). Fluoxetine
also decreases self-administration of cocaine in rats (M. E. Carroll, et al., 1990a), and acute
administration of fluoxetine has been shown to reduce the break point for cocaine in
progressive ratio studies (Richardson & Roberts, 1991). As further support of the role of the
serotonin system in modulating cocaine-like effects, acute administration of 8-OH DPAT, a
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5-HT1A receptor agonist, reduces responding for cocaine in a similar manner to fluoxetine
possibly implying that the reduction in responding seen with fluoxetine may be due to to
activity at the 5-HT1A receptor (Peltier & Schenk, 1993). Other studies have looked at the
effects of reducing brain 5-HT levels on cocaine self-administration. Administration of a 5HT neurotoxin (5,7-dihydroxytryptamine), which depletes levels of 5-HT in the brain,
increases the break point for cocaine self-administration when compared to vehicle control
animals (Loh & Roberts, 1990). Pre-treatment with l-tryptophan, which increases brain 5HT
levels, decreases the mean number of infusions obtained of low dose cocaine in rats (M. E.
Carroll, Lac, Asencio, & Kragh, 1990b).
These studies provide evidence suggesting that the serotonergic system plays a role in
modulating the behavioural effects of cocaine. It may be possible that a DAT inhibitor with
an appropriate level of SERT inhibition may be self-administered, but at lower levels than
cocaine. The aim of this experiment was to determine if increasing the level of SERT
inhibition alters self-administration of high affinity DAT inhibitors and if so, if there is an
optimum level of SERT inhibition that will attenuate cocaine-like self-administration
behaviour.

Hypothesis
Previous results from studies of this dissertation have shown that the selected test
compounds are behaviourally active and they all, at least partially, generalize to cocaine in
discrimination studies. Based on these data and reports that have indicated that DAT
inhibitors can, potentially, be self-administered, it is expected that cocaine and the test
compounds will be self-administered at some level. The literature discussed previously also
reported data indicating that SSRI’s are not reliably self-administered. It is possible that as
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the level of SERT inhibition is increased (from D-84>cocaine>GBR-12909>RTI-55) there
will be a decrease in self-administration.

Methods and Materials
Subjects
Adult, male, experimentally-naive Long-Evans hooded rats (Harlan Sprague-Dawley,
Indianapolis, IN) were used. Subjects were individually housed in an American Association
of Animal Laboratory Care-accredited facility and given ad libitum food and water. Free
feeding weights were obtained, and food (Harlan Teklad, Madison, Wisconsin) was
subsequently restricted to 15 g a day until rats achieved a target weight of approximately
320g. The rats were maintained at this target weight throughout the study by adjustments in
post-session feedings.

Self-administration Apparatus and Procedure
Self-administration tests were conducted in operant conditioning chambers housed
inside individual, isolated and ventilated boxes (Med-Associates Inc., St. Albans, VT). The
front wall of each chamber was equipped with two retractable levers with a white stimulus
light above each lever. A 5-w house light and Sonalert tone generator were located on the
rear wall of the chamber.
Infusion Assembly System
Catheters were constructed from polyurethane tubing (Access Technologies, Skokie,
IL; 0.044” O.D. X 0.025” WE.D.). The proximal 3.2 cm of the catheter was tapered by
stretching following immersion in hot sesame oil. The catheters were prepared with a
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retaining cuff approximately 3 cm from the proximal end of the catheter. A second larger
retaining cuff was positioned approximately 3.4 cm from the proximal end of the catheter.
Mid-scapula cannula/connectors (Plastics One, Roanoke, VA). The cannula/connectors
consisted of a threaded plastic post through which passed an “L” shaped section of 22 gauge
stainless steel needle tubing. The lower surface of the plastic post was affixed to a 2 cm
diameter disc of Dacron mesh. During experimental sessions the exposed threaded portion of
the infusion cannula was connected to an infusion tether consisting of a 35 cm length of 0.40
mm polypropylene tubing encased within a 30 cm stainless steel spring to prevent damage.
The upper portion of the 0.40 polypropylene tubing was connected to a fluid swivel (Lomir
Biomedical, Inc, Quebec, Canada) that was, in turn, attached via 0.40 polypropylene tubing
to the infusion syringe.

Surgical Procedure
Following acclimation to the laboratory environment, indwelling venous catheters
were implanted into the right external jugular vein. Surgical anesthesia was induced with a
combination of 50 mg/kg ketamine and 8.7 mg/kg xylazine. Rats were additionally
administered 8 mg/kg oral Baytril for three days post-surgery. The ventral neck area and back
of the rat were shaved and wiped with betadine and isopropyl alcohol. The rat was placed
ventral side down on the surgical table and a 3 cm incision was made 1 cm lateral from midscapula. A second 0.5 cm incision was then made mid-scapula. The rat was then placed
dorsal side down on the operating table and a 2.5 cm incision was made longitudinally
through the skin above the jugular area. The underlying fascia was bluntly dissected and the
right external jugular vein isolated and ligated. A small cut was made into the vein using an
iris scissors and the catheter was introduced into the vein and inserted up to the level of the
larger retaining cuff. The vein encircling the catheter between the two cuffs was then tied
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with silk suture. A second suture was then used to anchor the catheter to surrounding fascia.
The distal end of the catheter was passed subcutaneously and attached to the
cannula/connector that was then inserted subcutaneously through the larger incision. The
upper post portion of the connector/cannula exited through the smaller mid-scapula incision.
All incisions were then sprayed with a gentamicin/betamethasone valerate topical antibiotic
and the incisions were closed with Michel wound clips.
Rats were allowed to recover from surgery for at least 5 days before selfadministration training began. Periodically throughout training, methohexital (1.5 mg/kg) or
ketamine (5 mg/kg) was infused through the catheters to determine patency as inferred when
immediate anesthesia was induced. Between sessions the catheters were flushed and filled
with 0.1 ml of a 25% glycerol/75% sterile saline locking solution containing: 250 units/ml
heparin, 250 mg/ml ticarcillin, and 9 mg/ml clavulanic acid. If during the experiment a
catheter was determined to be in-patent, the left external jugular was then catheterized and
the rat was returned to testing.

Substitution of Test Compounds
Cocaine self-administration training sessions were 2 h in duration and were conducted
5 days a week (M-F), unless testing had begun, and then sessions were run continuously until
testing was completed. Initially, each response (fixed ratio 1, FR1) on the right-side lever
resulted in delivery of a 0.5-mg/kg cocaine infusion (0.18 ml/6 sec). For the duration of the
infusion, the tone sounded and the stimulus lights above both levers flashed at 3 Hz. Active
(right-side) lever presses during the infusions as well as all inactive (left-side) lever presses
were recorded but were without scheduled consequences. When neither increasing nor
decreasing trends in infusion numbers for three consecutive sessions had occurred, and the
rats had obtained at least 15 infusions during each session for at least 12 sessions, cue
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changes (stimulus light flashes above levers and Sonalert activations) during infusions were
discontinued. Discontinuation of cue changes was initiated to permit rapid extinction of lever
pressing during substitutions with doses of test drugs. After three sessions of
0.5mg/kg/infusion cocaine self-administration without cues during which neither increasing
nor decreasing trends in infusion numbers occurred, saline was substituted as the available
infusate until the number of infusions obtained during a session was less than 50% the mean
of the most recent three cocaine sessions. Rats were then returned to 0.5 mg/kg/cocaine
availability without cues until trends in infusion numbers did not occur across three
consecutive sessions. Vehicle, and increasing doses of GBR-12909 (0.1, 0.3, 1.0 and 1.3
mg/kg/infusion) were then substituted for three consecutive sessions each. Following tests
with GBR-12909, the rats were returned to 0.5 mg/kg/inf cocaine availability for three
consecutive sessions.
In a second group of rats, the same procedure was repeated but RTI-55 doses (0.001,
0.01, 0.03 and 0.1 mg/kg/infusion) were substituted for cocaine.

Data Analysis
For self-administration substitution studies, data from the last day of substitution at
each dose were used in the analyses. One-way repeated measures ANOVA, followed by
Dunnett’s post hoc tests, were used to compare self-infusions of drug from self-infusions of
saline. A compound is considered to be self-administered when its self-administration
infusions are statistically greater than vehicle control levels. Statistical significance was
assumed in all analyses if p<0.05. Statistical analyses and nonlinear regressions were
performed using GraphPad Prism version 5.0 for Mac OSX, GraphPad Software, San Diego,
California USA.
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Results
Self-administration of Cocaine and D-84
Fig. 2 (upper panel) shows the mean numbers of infusions obtained when cocaine and
D-84 were available for self-administration. The relationship between self-administered
cocaine infusions and dose was characterized by an inverted U-shaped curve with peak
numbers of infusions occurring at the intermediate cocaine dose of 0.1 mg/kg/infusion, which
was significantly greater than saline control numbers (p<0.05). D-84's self-administration
was also characterized by a U-shaped curve relating infusions to dose with peak numbers of
infusions occurring at 0.3 mg/kg/infusion, and which were significantly greater than vehicle
control numbers (p<0.05). Fig. 2 (lower panel) shows mean drug intake (mg/kg/2-session) of
self-administered cocaine and D-84. Mean drug intake for both cocaine and D-84 increased
as a function of dose. Peak levels of D-84 (21.6±4.61) intake were non-significantly lower
than peak levels of cocaine (24.3±3.34) intake.

Self-administration of GBR-12909
Fig.11 (upper panel) shows the mean numbers of infusions obtained when GBR12909 was available for self-administration. The relationship between self-administered
GBR-12909 infusions and dose was characterised by an inverted U-shaped curve with peak
numbers of infusions occurring at an intermediate dose of 0.3 mg/kg/infusion, which was
significantly greater than saline control numbers (p< 0.05). Fig.11 (lower panel) shows mean
drug intake (mg/kg/2-hr session) of GBR-12909. Mean drug intake increased as a function of
dose and peak levels of GBR-12909 intake (12.4 + 2.5) were significantly lower than peak
levels of cocaine (24.3±3.34) intake.(p<0.05, unpaired t-test).
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Self-Administration of RTI-55
Fig.12 (upper panel) shows the mean number of infusions obtained when RTI-55 was
available for self-administration. The relationship between self-administered RTI-55
infusions and dose was characterised by an inverted U-shaped graph with peak numbers of
infusions occurring at a dose of 0.01 mg/kg/infusion, which was significantly greater than
saline control numbers (P<0.05). Fig.12 (lower panel) shows mean drug intake (mg/kg/2-hr
session) of RTI-55. Mean drug intake increased as a function of dose. Peak levels of RTI-55
intake (2.14 + 0.12) were significantly lower than peak levels of all other tested drugs (p<
0.05 as shown by repeated measures ANOVA).
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Fig. 11 Self-administration of GBR-12909: Upper panel: Mean infusions of GBR-12909
vehicle (unfilled squares), and GBR-12909 (filled circles) obtained as a function of dose.
Brackets through data points indicate ±SEM. N=6 at all conditions. * = p< 0.05 as compared
to vehicle. Bottom panel: Mean drug intake (mg/kg/2-h session) as a function of dose. Other
details as described for the upper panel.

77

Fig. 12 Self-administration of RTI-55: Upper panel: Mean infusions of RTI-55 vehicle
(unfilled squares), and RTI-55 (filled circles) obtained as a function of dose.
Brackets through data points indicate ±SEM. N=5 at all conditions. * = p< 0.05 as compared
to vehicle. Bottom panel: Mean drug intake (mg/kg/2-h session) as a function of dose. Other
details as described for the upper panel.
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Discussion
The objective of this study was to determine if increasing the level of SERT inhibition
altered the cocaine-like self-administration effects of the selected DAT inhibitors. This was
achieved by the selection of three high affinity DAT inhibitors which varied, according to the
rationale set out in the introduction, in their intrinsic potency of SERT inhibition. All three
test compounds were reliably self-administered above vehicle control but maintained rates of
responding at lower levels than when cocaine was available for self-administration. The three
test compounds produced very similar mean infusions rates to each other. As the level of
SERT inhibition increased in the order of D-84>GBR-12909>RTI-55, peak intake of drug
decreased in the order of D-84>GBR-12909>RTI-55 and peak number of infusions decreased
in the order of D-84>RTI-55>GBR-12909.
Cocaine is a non selective, triple amine uptake inhibitor and is robustly selfadministered (Ritz, et al., 1987). D-84 is, to date, one of the most selective DAT inhibitors
currently available (NIDA Broad Spectrum Analysis), and has negligible activity at the
SERT. D-84 produced maximal infusion numbers lower than cocaine but similar to RTI-55
and GBR-12909. Given the observation that the presence of SERT inhibition can attenuate
cocaine self-administration (Howell & Byrd, 1995), and that activity at DAT is likely
responsible for cocaine's self-administration, the fact that D-84 is self-administered is not
surprising and further suggests that DAT inhibition, by itself, is sufficient to maintain selfadministration behavior. However, its incomplete generalization in cocaine discrimination
studies suggests factors other than SERT inhibition may play a role in D-84’s incomplete,
cocaine-like profile. SERT inhibition has been shown to attenuate cocaine self-administration
(M. E. Carroll, et al., 1990a) suggesting that the serotonergic system modulates cocaine selfadministration behaviour. Cocaine possesses a higher uptake inhibition at the SERT than D84 yet produces mean infusion numbers that exceed the mean infusion numbers produced
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with D-84. If SERT inhibition was the lone determinant for limiting self-administration of
high potency DAT inhibitor compounds, it may have been expected that D-84 would have
produced higher infusion numbers than even cocaine and the other test compounds. While
there are studies supporting the supposition that SERT inhibition attenuates cocaine selfadministration, the current data suggest that SERT inhibition may not be the only factor. It
has been reported that affinity at the DAT has a positive correlation with potency to maintain
responding in self-administration experiments (Bergman, et al., 1989; Ritz, et al., 1987), but
this does not explain the differences seen between cocaine and D-84, given that D-84 has a
higher DAT uptake inhibition affinity than cocaine. Some DAT compounds, with a higher
affinity for the DAT than cocaine, have a lower reinforcing efficacy and abuse potential when
compared to cocaine (Ferragud, et al., 2009; Lile, et al., 2002; Lile et al., 2003; Woolverton,
et al., 2001). It has been suggested that there are several binding sites on the DAT or multiple
DAT conformations and that, potentially, different compounds bind to different
sites/conformations. GBR-12909 and mazindol have been shown to bind to a site on the DAT
that is different from the cocaine binding site suggesting that more than one binding site or
conformation exists (Berger, Elsworth, Reith, Tanen, & Roth, 1990) and that these different
binding domains/conformations may produce variations in cocaine-like effects of high
affinity DAT inhibitors (J. L. Katz, Izenwasser, Kline, Allen, & Newman, 1999) (Chen &
Reith, 2007; Chen, Zhen, & Reith, 2004). It may be possible that cocaine and the test drugs
differ in their affinities for these different binding sites/conformations and that binding at the
different sites/conformations may convey different levels of cocaine-like activity. Therefore,
DAT uptake inhibition affinity alone may not be responsible for cocaine’s abuse related
effects, a consideration which may help explain the current data showing D-84 maintaining a
lower mean rate of infusion when compared to cocaine, despite having a higher DAT uptake
inhibition affinity.
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GBR-12909 has intermediate inhibitory effects at the SERT and results from this
study confirm previous findings that GBR-12909 is self-administered in pre-clinical animal
models (Andersen, 1987; van der Zee, et al., 1980). RTI-55 is a high DAT, high SERT
(Boja, Cline, et al., 1992) inhibitor and findings from the current study also confirm previous
studies that it maintains rates of self-administration above vehicle control level in rhesus
monkeys (Weed, et al., 1995) . Mean drug intake differed between the test compounds,
descending in the following order D-84>GBR-12909>RTI-55. This trend follows the level of
SERT inhibition in the test compounds with D-84 having the least and RTI-55 having the
most SERT inhibition activity. This may suggest that an increase in SERT inhibition
produces a decrease in drug intake. All three test compounds were self-administered above
vehicle control levels, and definitive conclusions about their relative reinforcing efficacies
cannot be determined from the current data. Studies more directly addressing relative
reinforcing efficacy (e.g., progressive ratio or choice studies) are required before it is possible
to make more definitive statements regarding the relative reinforcing efficacies of these
compounds as a function of the level of SERT inhibition.

Based on the available literature, it is thought that the presence of serotonin, via
uptake inhibition, can attenuate cocaine self-administration (Alex & Pehek, 2007; M. E.
Carroll, et al., 1990a), and it is known that serotonergic agonists and SERT inhibitors are not
self-administered themselves (Howell & Byrd, 1995). This suggests that compounds that
promote an increase in serotonergic activity should have less cocaine-like effects and,
presumably, as you increase this level of SERT inhibition from minimal levels in a selective
DAT inhibitor like D-84, to high levels in a compound like RTI-55, there should be a
descending level of cocaine-like effects. However, although the test compounds were selfadministered less than cocaine, it seems that the large changes in SERT inhibition did not
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produce comparable changes in cocaine-like behavioural effects between the drugs. This may
suggest that an increase in SERT inhibition alone with these compounds was not sufficient to
produce the predicted effects.
In the current studies RTI-55 maintained rates of responding at non-significantly
higher levels than GBR-12909, despite having a higher uptake inhibition affinity at the
SERT. This may imply that, whilst a level of SERT inhibition may be important for reducing
cocaine-like behavioural effects (since they all were self-administered less than cocaine), it
may not be the only factor involved. RTI-55 has a Ki value for inhibiting reuptake of DA of
1.6 nM compared to 10.6 nM for GBR-12909 and 4.05nM for D-84, and it has been
established that there is a correlation between DAT affinity and self-administration (Kuhar,
Ritz, & Boja, 1991; Ritz, et al., 1987). It is possible that these high DAT uptake inhibition
affinities may be producing a higher level of DAT inhibition than can be attenuated by the
level of available SERT inhibition which may explain the lack of significant differences in
infusion numbers seen between the test compounds.
The level of DAT occupancy influences the reinforcing properties of compounds
(Volkow, Wang, Fischman, et al., 1997). Human neuro-imaging studies have shown that
there is a strong correlation between DAT occupancy and the subjective high reported
following acute administration of cocaine (Volkow, Wang, Fischman, et al., 1997). Studies
have shown that doses of cocaine that maintain peak response rates in self-administration
result in DAT occupancy between 65% and 76% in rhesus monkeys (Wilcox et al., 2002).
Further studies have shown that doses of GBR-12909 that decrease cocaine selfadministration in rhesus monkeys result in DAT occupancy of approximately 50% (Lindsey
et al., 2004). Since the test compounds all have high uptake inhibition affinity at the DAT, it
may be possible that this high level of DAT inhibition could be producing a level of DAT
occupancy that may be insurmountable by any level of SERT inhibition. Finally, the
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pharmacokinetics of these compounds could be playing a role in their self-administration
effects. It has been shown that a rapid onset is positively related to reinforcing and subjective
effects of drugs (Balster & Schuster, 1973). It has also been shown that, when using FR
schedules, as in this current study, drugs with a longer duration of activity tend to maintain
lower rates of responding than drugs with shorter durations (Balster & Schuster, 1973;
Winger, Stitzer, & Woods, 1975). As reported in chapter three, all of the current test
compounds had durations of activity that were much longer than cocaine, and this
pharmacokinetic effect may be playing a role in the differences in responding seen between
cocaine and the test compounds.
The goal of this study was to determine if an increase in SERT inhibition decreased
self-administration. Although the test compounds all maintained lower rates of responding
than cocaine, they did not differ as greatly from each other as expected, despite the large
differences in SERT inhibition. It may be possible that multiple ligand binding sites on the
DAT, DAT receptor occupancy, or pharmacokinetics may, alone or in sum, be reducing the
potential control that SERT inhibition may have on self-administration of these drugs, and
therefore, while these data may help support previous findings that SERT inhibition does
have an attenuating effect on cocaine-like self-administration behavior (M. E. Carroll, et al.,
1990a, 1990b), the current results with D-84 underscore the complexity of the possible
determinants which may exert such control.
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SUMMARY OF RESULTS AND OVERALL DISCUSSION

This dissertation consisted of two components, the research for which were conducted
sequentially, although the results were discussed concurrently (Table 2). The first component
tested whether an extremely selective DAT inhibitor (D-84), being nearly devoid of
serotonergic and noradrenergic activity, had a pharmacology which was suitable as a
potential replacement therapy for cocaine dependency. The results demonstrated that D-84,
possessed characteristics deemed favourable, although perhaps not ideal, as a cocaine
replacement therapeutic. D-84 had a long duration of action in locomotor activity studies (>4
h), incompletely generalized to cocaine in discrimination studies (76%), attenuated cocaine
self-administration and was self-administered above vehicle control levels. Incomplete
generalization in the discrimination studies replicated earlier findings in the mouse (Ghorai,
et al., 2003), strenthening its perception of partial generalization while extending it to another
species. The second component of the dissertation examined whether manipulating the
presence of serotonergic activity could be an additional approach for which to control
cocaine-like effects of DAT inhibitors.
As described in Chapter Three, research has provided evidence suggesting that the
serotonergic system can be manipulated for modulating the positive reinforcing effects of
cocaine-like compounds (Callahan & Cunningham, 1997; Cunningham & Callahan, 1991;
Simon & Appel, 1997). Attempting to understand if the proportional level of serotonergic
activity can modulate cocaine-like behavioural effects of DAT inhibitors was the basis for the
second part of this dissertation. The current results showed that D-84 (High DAT, low
SERT), GBR-12909 (High DAT, medium SERT) and RTI-55 (High DAT, High SERT)
compounds had longer durations of action than cocaine and showed that an increase in SERT
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inhibition correlated with lower peak total distance travelled in locomotor activity studies.
As SERT inhibition increased from D-84<cocaine<GBR-12909<RTI-55, peak locomotor
activity decreased in reverse order from RTI-55>GBR-1209>cocaine>D-84, suggesting the
possibility that an increase in SERT inhibition may be producing decreases in peak activating
effects. D-84 and GBR-12909 had similar onsets and durations of action, despite differing
greatly in their levels of SERT inhibition, and so it seems that other factors interacted with
increasing SERT to control locomotor activity. RTI-55 possessed the highest level of SERT
inhibition and showed the slowest onset of activity, starting at 20 min post-injection
compared to 10 min for all other compounds. With the exception of D-84, all the test
compounds completely generalized (>80%) to cocaine in discrimination studies and all the
drugs were self-administered significantly above vehicle control levels, but maintained
maximal rates of responding at levels lower than cocaine. In the absence of additional tests
(e.g., progressive ratio or choice tests), however, it is not possible to state uncategorically the
absolute reinforcing efficacy of each test drug in this study. As stated earlier, it has been
hypothesized

that potent affinity at the DAT is responsible for the reinforcing effects

produced by cocaine (Ritz, et al., 1987), and observing that D-84, GBR-12909 and RTI-55
are self-administered, it is likely that their self-administration is due to their binding at the
DAT. Additional studies are required in order to determine how increasing the level of SERT
alters the reinforcing efficacy of the selected test compounds. This study provided data
showing that the test compounds differed from cocaine in terms of their peak infusion
numbers, although not significantly from each other given the analysis conducted, suggesting
the need for additional studies to further isolate the exact influence of serotonin on these
cocaine-like behaviours. It is possible that the selected compounds did not differ greatly
enough in terms of their SERT inhibition affinities, and that more information could be
gathered from repeating these studies with a more disparate group of test compounds.
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Given the differences in SERT inhibition that the test compounds possess (see Tables
1 and 2), combined with the closeness of effects between the drugs in the discrimination and
self-administration assays, it is not possible to deduce what SERT inhibition, by itself, is
having on the recorded behaviours investigated in the current studies. DAT occupancy levels
and binding kinetics should also be considered to potentially be playing an important role. It
has been hypothesized that more than one binding site exists on the DAT available for
cocaine and other ligands to bind, that different DAT conformations play a role in drug
binding, or that additional relevant cocaine binding sites exist outside DAT (Berger, et al.,
1990; Boja, Markham, Patel, Uhl, & Kuhar, 1992; Rothman et al., 1994). Differences in
binding sites/conformations may potentially convey differences in behaviour which may help
explain some differences in cocaine-like behaviour seen with the compounds. Izenwasser
(1994) showed a positive correlation between DAT binding affinities and potencies for
stimulating locomotor activity for cocaine and cocaine analogues. However, the same study
failed to show a significant correlation between DAT binding potency and potency for
inducing locomotor activity for DAT inhibitors from a different structural class from cocaine,
suggesting that cocaine and other DAT inhibitors may produce locomotor activating effects
through different binding mechanisms. Binding studies with the current test drugs in relation
to locomotor activating effects could be helpful in determining how the compounds are
influencing locomotor activity and could provide information as to how important the level of
SERT inhibition is in comparison to binding profiles.
Since the results produced in the current discrimination and self-administration
studies were not consistent with, at least in magnitude, with the experimental predictions,
other potential explanations for the results should be examined. It was hypothesized that an
increase in SERT inhibition would decrease peak locomotor activating effects, decrease
generalization and decrease self-administration. The locomotor activity results generally
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produced the expected findings, but results obtained with discrimination and selfadministration were more equivocal. One other potential explanation for the results produced,
independent of SERT inhibition, could be related to the level of DAT receptor occupancy
produced by the test compounds or the level of increased extracellular DA produced on
administration of the compounds. Studies using brain imaging techniques identified a positive
relationship between an increase in neurotransmitter release in DA brain areas and the
intensity of the subjective high associated with cocaine (Volkow et al., 1996; Volkow, Wang,
& Fowler, 1997). Doses of cocaine that are commonly abused by human users have been
shown to result in a DAT occupancy between 67% and 69% in baboons (Volkow, et al.,
1996), and doses of cocaine that maintain peak rates of cocaine self-administration result in
DAT occupancy of 65%-76% in rhesus monkeys (Wilcox, et al., 2002). Microdialysis studies
have shown that drugs which fail to generalize to cocaine in discrimination studies do not
significantly increase extra-cellular levels of DA in the nucleus accumbens (Desai, Paronis,
Martin, Desai, & Bergman, 2010). This same study showed that acute administration of
cocaine produces a rapid increase in DA levels whilst administration of GBR-12909 produces
a slower, longer lasting peak. This confirms an earlier study that showed that GBR-12909 has
a slower onset of action, possibly due to this slower increase in DA levels, which potentially
could be a factor in the apparent low abuse liability possessed by GBR-12909 (Baumann et
al., 2002). These factors need to be considered when discussing the present results since these
factors could play a role that may supercede the importance of the level of SERT inhibition.
Although there is evidence in the literature to suggest that increasing SERT inhibition can
decrease cocaine-like effects, there are obviously other factors that need to be considered.
Cocaine produces its positive reinforcing effects through inhibitory action at the DAT
(Ritz, et al., 1987; Spealman, et al., 1989), and as a consequence, much drug development has
concentrated on using DAT inhibitors as potential replacement therapies (F. I. Carroll,
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Howell, & Kuhar, 1999). One challenge for any replacement therapy for cocaine dependence
is in developing effective compounds that have a safer abuse liability profile relative to
cocaine. Cocaine has a fast onset of action which is considered to be a factor in its abuse
liability (Balster & Schuster, 1973) and a short duration of action. It is thought that an
effective treatment for cocaine dependence would benefit from possessing a slower onset and
longer duration of action to minimize abuse while allowing for practical dosing schedules (F.
I. Carroll, et al., 1999; Howell, et al., 2000). With this in mind, much focus of the search for a
treatment for cocaine dependence has been on DAT inhibitors with a lower level of abuse
liability than cocaine (F. I. Carroll, et al., 1999; Gorelick, 1998; Gorelick, et al., 2004). DAT
inhibitors have been shown to generalize to cocaine in discrimination studies, albeit it at
different degrees of substitution (Balster et al., 1991; J. L. Katz, et al., 2001; Newman, et al.,
1994). Bupropion, for example, has high uptake inhibition at the DAT, and since this activity
is known to be responsible for the high abuse liability of cocaine-like psychostimulants, it is
not surprising that pre-clinical studies have shown bupropion to be self-administered in
monkeys and rats at levels similar to cocaine (Bergman, et al., 1989; Tella, et al., 1997).
These pre-clinical data, however, are not supported by the available epidemiological data that
have shown bupropion to have been minimally abused during its many years as an approved
anti-depressant and smoking cessation aid (Nieuwstraten et al., 2001, Wilkes, 2008). These,
and other data, suggest that DAT inhibitors, whilst conveying cocaine-like effects in preclinical studies, may not necessarily always possess abuse liability. Results with D-84
provide data that show incomplete generalization to cocaine in discrimination tests, and raises
the possibility that a high affinity and selective DAT inhibitor may possibly have a lower
abuse liability than cocaine. Without explicitly design tests (e.g., progressive ratio or choice
tests), however, it is not possible to make more solid predictions regarding the potential abuse
liability of D-84.
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Although a large body of the currently available data has focused on DAT inhibitors
as potential replacement therapies for cocaine, there are alternative possibilities for drug
developmental approaches. It has become evident that the serotonin system can modulate
some of the behavioral effects mediated by the dopaminergic system (D. A. Baker, TranNguyen, Fuchs, & Neisewander, 2001; Bubar & Cunningham, 2006; Burmeister, Lungren, &
Neisewander, 2003; Callahan & Cunningham, 1995, 1997), and it was this knowledge that
stimulated the research contained within the second component of this dissertation. The
serotonergic system is ideally placed to modulate dopaminergic neurotransmission due to
projections and innervations into the mesolimbic dopamine system, particularly the VTA and
NA (Herve, Pickel et al. 1987; Phelix and Broderick 1995). It is possible that serotonin can
act to decrease the firing rate of DA neurons causing a decrease in extracellular DA or by
decreasing DA release from neurons (Di Mascio, Di Giovanni, Di Matteo, Prisco, &
Esposito, 1998). The serotonergic system's ability to modulate cocaine-like behavioural
effects may also be due to inhibiting the cocaine-induced increase in extracellular dopamine
(Howell & Kimmel, 2008). It is possible that there is a optimum level of SERT inhibition that
may limit the potential cocaine-like abuse liability effects of other DAT inhibitors and, a
DAT inhibitor with an optimum level of SERT inhibition may be one way to produce a
desired profile for a cocaine replacement therapy. This desired profile could be a compound
with a high enough level of DAT inhibition to convey some cocaine-like behavioural effects,
combined with a level of SERT inhibition that would constrain its abuse liability. Such a
compound could potentially be an effective treatment for cocaine dependence but, to date,
clinical evaluations have not identified a suitable candidate with this right balance of effects.
Evidence has suggested that there are multiple binding sites on or multiple
conformations of the DAT (Berger, et al., 1990) and that cocaine binding may be better
described by a two site binding model as opposed to a one site model (Madras, Fahey,
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Bergman, Canfield, & Spealman, 1989). Low and high affinity binding sites have been
identified and it has been determined that binding to the high affinity site is responsible for
the abuse related effects seen with cocaine (J. L. Katz, et al., 1997), and in particular is
thought to play a vital role in the discriminative stimulus effects of cocaine (Katz, Izenwasser
et al., 2000). As mentioned earlier, certain DAT inhibitors bind to the DAT and inhibit DA
uptake but do not possess effects predictive of a high abuse potential (J. L. Katz, et al., 2001;
J.L Katz, et al., 2003). This could be explained by different compounds preferring different
DAT conformations (Reith et al., 2001; Loland et al., 2008; Schmitt et al., 2008). With the
dual binding sites observed for cocaine-like compounds (Madras, Fahey et al., 1989; Boja et
al., 1992), it is possible that some DAT inhibitors bind with higher affinity to the low affinity
site as opposed to the high affinity site resulting in low cocaine-like discriminative stimulus
effects. This activity could help explain the effects seen with D-84 which is a highly selective
DAT inhibitor yet fails to fully generalize to cocaine in discrimination studies. These low and
high affinity binding sites on the DAT could be considered as an alternative explanation for
the difference in effects produced with cocaine, RTI-55 and GBR-12909 when compared to
D-84 and cocaine. It is possible that binding affinities of these compounds at the different
binding sites on the DAT may play a predominant role in producing cocaine-like
discriminative stimulus effects, thereby reducing the influence of SERT inhibition. If a
reliable receptor binding protocol could be developed to quantifiably distinguish these
different binding sites, studies comparing RTI-55, GBR-12909 and D-84 with cocaine could
be carried out to compare individual Ki values in such controlled binding experiments with
ED50 values for occasioning cocaine generalization in an attempt to determine how the
binding site may be influencing the discriminative stimulus effects of the test compounds.
However, it should be noted that the pharmacological profile of the low-affinity binding site
for cocaine-like compounds has not been clearly established, and that conditions reliably
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producing a two-site binding phenomenon for such drugs has been elusive (Coffey & Reith,
1994; Reith & Coffey, 1994). Be that as it may, recent studies lending support for multiple
sites on DAT for inhibitors and substrates have been inspired by the structural
characterization of a bacterial homolog of the DAT, the leucine transporter (LeuT)
(Yamashita et al., 2005). Shi et al. (2008) advanced evidence for two sites for the substrate
leucine, one deep in the central cavity of the protein close the site for Na+ (crucial for
transport), and one more externally in the periplasmic vestibule. The distance between these
sites, ~ 11-13 Å, fits the distance between the two heads of bivalent dopamine- and
amphetamine-like ligands when bound and docked in human DAT (Schmitt, Mamidyala,
Biswas, Dutta, & Reith, 2010). In this context, it is of interest that Nielsen et al. (2009)
reported affinity gains for DAT, SERT, and NET of up to 45-fold for bivalent phenyl
tropanes (of the same template as RTI-55) when tethered together with an ester linker of 10
atoms, again bridging binding sites separated by a distance of ~13 Å. The results point to a
secondary binding site in DAT that has affinity for both DA-like substrates and
phenyltropane-like inhibitors.
The second overall aim of this study was to determine if increasing SERT inhibition
attenuated cocaine-like behavior in three different rodent assays. Whilst the results showed
differences between cocaine and the test compounds in locomotor activity, in terms of peak
effects and duration of action, differences in drug discrimination and self-administration were
not as pronounced. In the discrimination studies, GBR-12909 (SERT Ki 73 nM) and RTI-55
(SERT Ki 3.8 nM) both completely generalized to cocaine despite their differences in SERT
inhibition, and all three compounds were reliably self-administered above vehicle control
levels. It may be harder than first thought to determine the exact influence SERT inhibition
has over the cocaine-like behaviour produced by DAT inhibitors, at least when limited to the
behavioural assays conducted in the current dissertation. Although the locomotor activity and
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discrimination data showed a decrease in cocaine-like activity as SERT inhibition was
increased, it is not possible to determine what level of SERT inhibition produces these
attenuating effects. It is known that SSRI’s are not self-administered (Gold & Balster, 1991)
but can attenuate cocaine self-administration (M. E. Carroll, et al., 1990a) and can modulate
cocaine’s discriminative stimulus cue (Callahan & Cunningham, 1997; Cunningham &
Callahan, 1991; Filip, et al., 2006) . It is also known that cocaine and other DAT inhibitors
can stimulate locomotor activity (Cline et al., 1992), are self-administered and can generalize
to cocaine in discrimination studies (Ritz, et al., 1987; Spealman, et al., 1989). This suggests
that it may be possible to decrease the level of SERT inhibition from that equivalent in an
SSRI to that associated with selective DAT inhibitor potentially resulting in a shift from noncocaine like behavior to cocaine-like. Where that shift occurs has yet to be determined and
the data from this study does not conclusively identify the level of SERT inhibition required
in order to change a compound from cocaine-like to not cocaine-like. In fact, data with D-84
suggests multiple determinants are operative in controlling the level of cocaine-like
behavioral expression in DAT inhibitors, and that SERT inhibition may only be one of them.
Determining the level of SERT inhibition needed to reduce cocaine-like effects may
be complicated by the complexity of the serotonergic system itself. Data have shown that the
5-HT2 system is important in modulating cocaine-like behavioural effects of DAT inhibitors
(Filip, et al., 2006; Higgins & Fletcher, 2003), however, the 5-HT2A and 5-HT2C receptor
systems seem to play opposing roles. Activation of the 5-HT2C receptor system mediates an
inhibitory effect on the dopaminergic systems (Di Matteo, De Blasi, Di Giulio, & Esposito,
2001), possibly through interaction with inhibitory GABA neurons (Eberle-Wang,
Mikeladze, Uryu, & Chesselet, 1997), whilst activation of the 5-HT2A system has been shown
to enhance it (Alex & Pehek, 2007). An increase in extracellular 5-HT following SERT
inhibition leads to activation of 5-HT2A/C receptors, and, given some of the opposing actions
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just mentioned between 5-HT receptor subtypes, activation of these receptors may have
opposing effects on dopaminergic neurotransmission, and hence, have opposing effects in
modulating cocaine-like behaviour. Depending on the net activation of 5-HT2C vs 5-HT2A, an
increase in serotonergic tone could either attenuate cocaine-like effects or enhance it, and it
may be possible to elucidate the role of SERT inhibition in modulating cocaine-like effects if
it was known which of the 5HT receptors are more influenced by this increase in extracellular
5-HT. These modulating effects of 5-HT

2A/2C

agonists have been previously reported with

another CNS active compound, nicotine. Non-selective 5-HT 2A/2C agonists have been shown
in our laboratory to blunt the locomotor activating and discriminative stimulus effects of
nicotine in rats (Batman, Munzar, & Beardsley, 2005) providing a further example by which
SERT inhibition may attenuate dopaminergic-mediated activity.
The current study has reinforced reports indicating that DAT inhibitors stimulate
locomotor activity, at least partially generalize to cocaine in discrimination studies, and can
be self-administered. There are also reports indicating that SERT inhibitors can have an
inhibitory influence over cocaine-like effects (Burmeister, et al., 2003; Callahan &
Cunningham, 1995; M. E. Carroll, et al., 1990a). The results from the current studies are
summarized in table two, and do not conclusively confirm that an increase in SERT
inhibition is responsible for the decrease in cocaine-like effects, although the results do show
a trend in that direction in the locomotor activity studies. All of the compounds were selfadministered significantly above vehicle control levels but they differed in their maximum
levels of drug intake. This effect may be related to the potency of the drugs in this assay.
RTI-55 was the least potent of the drugs in stimulating locomotor activity but the most potent
in self-administration (and discrimination) studies which may explain its very low drug intake
levels in self-administration. However, this could also be related to its intrinsic reinforcing
efficacy, but results from the current studies cannot categorically establish this without data
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from additional studies. The results with RTI-55 could imply that SERT inhibition may be
playing more of a role in modulating cocaine-like locomotor activity behaviour, as opposed
to discrimination and self-administration behaviour, and may suggest that the effects of
SERT inhibition may be dependent on the variable being measure.
It should be noted that not all selective DAT inhibitors are created equally. As
mentioned previously, and as shown by discrimination results with D-84, not all selective
DAT inhibitors produce complete cocaine-like behaviour. D-84 only partially generalized to
cocaine in discrimination studies despite being a very selective and potent DAT inhibitor.
Although it is possible that SERT is playing a role in attenuating cocaine-like effects of some
DAT inhibitors, results obtained with D-84 indicate that SERT inhibition is not the only
factor that can attenuate cocaine-like behaviour. SERT inhibition, pharmacokinetics, receptor
occupancy and exact binding site may all be playing a role. All contributing factors may need
to be considered in order to develop a successful replacement therapy in cocaine dependency.
As mentioned, this dissertation was divided into two sections with the first section
concentrating on elaborating the pharmacology of a selective DAT inhibitor as part of a drug
development effort. These data, while not conclusive, suggests that a selective DAT inhibitor
such as D-84, may reduce cocaine self-administration and may possess a lower abuse liability
than cocaine. Understanding how this compound produces its composite effects would help
focus future drug developmental efforts.

The second component of this dissertation tested whether manipulating the level of
SERT could be an effective approach for manipulating the expression of cocaine-like
behavioral activity of DAT inhibitors. The current data (summarized in Table 2, following
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this Discussion) shows that an increase in SERT inhibition correlates with a decrease in
locomotor stimulating effects. These same data, with the exception of D-84, fail to show any
significant effect of SERT inhibition on cocaine-like discrimination behaviour, and in fact,
the discrimination results with D-84 complicates these interpretations. Finally, since all three
test compounds were reliably self-administered above vehicle control levels, the data suggest
that the differences in SERT inhibitory action in the currently tested compounds do not
produce significant changes in self-administration.
Although the current data failed to determine if there is an optimum level of SERT
inhibition required to attenuate the abuse related effects of cocaine, the hypothesis that SERT
inhibition can, in fact, attenuate the reinforcing effects of cocaine, should still be kept in the
forefront of research. Recent studies have suggested that introducing substitutions into the
chemical structures of SSRI’s such as fluoxetine, can produce a new generation of DAT
inhibitors with a much lower apparent abuse potential than cocaine (Yoon, Cho, Yoon, Min,
& Lee, 2009). This recent study strengthens the hypothesis that manipulating the serotonin
system can reduce the cocaine-like positive reinforcing effects of DAT inhibitors, and this
approach still may contribute to a replacement therapy for cocaine dependence.
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Table Two: Overall Summary of Results
Locomotor Activity
Compound

DAT (ki nM)

D-84
Cocaine
GBR-12909
RTI-55

4.05
478
4.3
1.6

1
ii

SERT (ki nM)

1274
304
73
3.8

LMA peak
distance
travelled
(cm)
3500
3000
1600
1500

LMA
area
under
curve
(cm2)
10312
10276
6174
5348

Drug
Discrimination
DLR
RR
ED50
ED50
(mg/kg)

(mg/kg)

8.2
2.85
9.02
2.32

33.9
13.83
i

5.97

Self-administration
Dose at peak selfMaximum
administered
intake (mg/kg)
infusions ii
(mg/kg/inf)
0.3
0.1
0.3
0.01

GBR-12909 produced non-significant reductions in response rates at the dose range tested
Self-administration is defined as any dose where mean infusions> saline infusions
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21.6
24.3
12.3
2.14
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GBR-12909 produced non-significant reductions in response rates at the dose range tested
Self-administration is defined as any dose where mean infusions> saline infusions

109

